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ABSTRACT
Microfluidic Devices with Integrated Sample Preparation for Improved Analysis of Protein
Biomarkers
Pamela N. Nge
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Biomarkers present a non-invasive means of detecting cancer because they can be obtained from
body fluids. They can also be used for prognosis and assessing response to treatment. To limit
interferences it is essential to pretreat biological samples before analysis. Sample preparation
methods include extraction of analyte from an unsuitable matrix, purification, concentration or
dilution and labeling. The many advantages offered by microfluidics include portability, speed,
automation and integration. Because of the difficulties encountered in integrating this step in
microfluidic devices most sample preparation methods are often carried out off-chip. In the
fabrication of micro-total analysis systems it is important that all steps be integrated in a single
platform.
To fabricate polymeric microdevices, I prepared templates from silicon wafers by the process of
photolithography. The design on the template was transferred to a polymer piece by hot
embossing, and a complete device was formed by bonding the imprinted piece with a cover
plate. I prepared affinity columns in these devices and used them for protein extraction. The
affinity monolith was prepared from reactive monomers to facilitate immobilization of
antibodies. Extraction and concentration of biomarkers on this column showed specificity to the
target molecule. This shows that biomarkers could be extracted, purified and concentrated with
the use of microfluidic affinity columns.
I prepared negatively charged ion-permeable membranes in poly(methyl methacrylate)
microchips by in situ polymerization just beyond the injection intersection. Cancer marker
proteins were electrophoretically concentrated at the intersection by exclusion from this
membrane on the basis of both size and charge, prior to microchip capillary electrophoresis. I
optimized separation conditions to achieve baseline separation of the proteins. Band broadening
and peak tailing were limited by controlling the preconcentration time. Under my optimized
conditions a 40-fold enrichment of bovine serum albumin was achieved with 4 min of
preconcentration while >10-fold enrichment was obtained for cancer biomarker proteins with
just 1 min of preconcentration.
I have also demonstrated that the processes of sample enrichment, on-chip fluorescence labeling
and purification could be automated in a single voltage-driven platform. This required the
preparation of a reversed-phase monolithic column, polymerized from butyl methacrylate
monomers, in cyclic olefin copolymer microdevices. Samples enriched through solid phase
extraction were labeled on the column, and much of the unreacted dye was rinsed off before
elution. The retention and elution characteristics of fluorophores, amino acids and proteins on

these columns were investigated. A linear relationship between eluted peak areas and protein
concentration demonstrated that this technique could be used to quantify on-chip labeled
samples. This approach could also be used to simultaneously concentrate, label and separate
multiple proteins.

Keywords: biomarkers, capillary electrophoresis, capillary electrochromatography,
microfluidics, sample preparation
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1. INTRODUCTION *
1.1 MINIATURIZED BIOANALYTICAL SYSTEMS
1.1.1 Introduction to micro-total analysis systems (µTAS)
Microfluidics consist of microfabricated structures for liquid handling, with cross-sections in the
1-500 µm range, and small volume capacity (fL-nL). Though micromachined systems for gas
chromatography were introduced in the 1970’s,1 the field of microfluidics did not gain much
traction until the 1990’s.2 Microelectromechanical systems (MEMS) contain integrated electrical
and mechanical parts that create a sensor or system.3 Micro-total analysis systems, also known as
lab-on-a-chip, are the chemical analogues of MEMS, as integrated microfluidic devices that are
capable of automating multiple processes relevant to laboratory sciences. For example, a typical
lab-on-a-chip system can integrate multiple processes (like labeling, purification, separation, and
detection) in a microfluidic device, which can be highly enabling for many applications.

The field of microfluidics offers many advantages compared to bulk solution chemistry, one of
which is faster diffusion rates due to the smaller interaction distances. Reduced channel
dimensions also lead to smaller sample volumes (fL-nL), as well as portable devices that enable
on-site testing, for example. Due to the multitude of advantages of microfluidics, many
applications have been demonstrated, often with a biological focus such as point-of-care (POC)
diagnostics, single-cell analysis, nucleic acid analysis, drug discovery and development, or
biosensing.4 Additional applications are found in environmental monitoring, forensics, food
analysis and space exploration.
* Parts of this chapter are adapted with permission from Chemical Reviews, Nge, P. N.; Rogers, C. I.; Woolley, A.
T., Chem. Rev. 2012, In revision. Copyright 2012 American Chemical Society.

1.1.2 Materials
Microfluidic device materials initially consisted of silicon and glass substrates; as the field
advanced, other materials were evaluated. These materials can be organized into three broad
categories: inorganic, polymeric, and paper. Polymer-based materials can be further divided into
elastomers and thermoplastics. Paper microfluidics is an emerging and substantially different
platform from devices made from either polymer or inorganic materials.

Silicon, the first material used for microfluidics,1 has a well-developed surface chemistry based
on the silanol group (–Si-OH), so surface modification is easily accomplished via silanes. Silicon
is transparent to infrared but not visible light, making typical fluorescence detection or fluid
imaging challenging for embedded structures in silicon. This issue can be overcome by having a
transparent material (polymer or glass) bound to silicon in a hybrid system. Glass has large,
composition-dependent elastic modulus, low background fluorescence, and as with silicon,
modification chemistries are silanol based. Glass is compatible with biological samples, has
relatively low nonspecific adsorption, and is not gas permeable.

Polymers are organic-based, long-chain materials that are increasingly being used for
microfluidic device fabrication because they are relatively inexpensive, amenable to mass
production processes and adaptable through formulation changes and chemical modification.
Polydimethylsiloxane (PDMS), first introduced as a microfluidic substrate in the late 1990’s,5 is
arguably the most common material in use due to its reasonable cost, rapid fabrication, and ease
of implementation. A hydrophobic material, PDMS is susceptible to nonspecific adsorption and
permeation by hydrophobic molecules.6 However, chemical modification of PDMS by methods

2

such as plasma treatment7 and reaction of silanes with silanols8 can often address these issues.
Thermoplastics are densely crosslinked polymers that are moldable when heated above their
glass transition temperature but retain their shape when cooled. These materials are generally
durable, amenable to micromachining processes, optically clear, resistant to permeation of small
molecules, and stiffer than elastomers. The most frequently used thermoplastic is poly(methyl
methacrylate) (PMMA), formed through the polymerization of methyl methacrylate and better
known under the commercial names of Plexiglas or Lucite. PMMA has an elastic modulus of 3.3
GPa and good optical clarity.9 Other advantages of this material include biological compatibility,
gas impermeability, and ease of micromachining at relatively low temperatures (~100°C).
Cyclic-olefin copolymer (COC)10 is an optically transparent thermoplastic, with good
moldability, low background fluorescence, and suitability for use with both organic solvents and
aqueous solutions.11, 12 Since COC is hydrophobic, surface modification is necessary to analyze
proteins in these devices.10

Paper is a flexible, cellulose-based material that has recently emerged as a promising
microfluidic substrate because it is cheap, readily available, biologically compatible and can be
chemically modified through composition/formulation changes or through surface reactions.13, 14
Microfluidic paper-based analytical devices (µPADs) rely on the passive mechanism of capillary
action to pull solutions through a device. They are potentially useful for quantitative analysis in
developing countries, home care services and other places where resources are limited,15 and
generally employ colorimetric or electrochemical detection that does not require complex
instrumentation.16 Initially, µPADs were one-dimensional devices that had some limitations
including loss of fluid by evaporation and increased chances of contamination during analysis.
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More complex three-dimensional µPADs address some of the problems observed with onedimensional devices.17,18

1.1.3 Fabrication techniques
Fabrication of microfluidic devices involves several techniques depending on the type of
material. Most of the techniques for the fabrication of silicon and glass devices are adapted from
the semiconductor industry and are either subtractive processes in which structures are formed
within the substrate (bulk micromachining), or additive processes in which structures are formed
on the surface of the substrate (surface micromachining). In this section, only the more common
bulk micromachining processes will be discussed.

1.1.3.1 Glass and silicon devices
Conventional microfabrication techniques for glass and silicon devices involve photolithography,
etching and bonding. In photolithography the desired microchannel design is patterned on a
photomask and subsequently transferred to the silicon or glass. First the substrate is coated with a
light-sensitive photoresist and exposed to UV radiation using a mask aligner. During the process
of chemical development for a positive photoresist, the exposed region is removed while the
parts not exposed to light stay intact. The reverse occurs for a negative photoresist. Features on
the substrate are then created by etching, which can either be done in the liquid or gas phase,
with isotropic or anisotropic directionality. This is followed by bonding. Bonding methods
include direct bonding,19 anodic bonding20 and use of adhesives21 such as Parylene C, SU-8,
benzocyclobutene, and polyimide.22
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1.1.3.2 Polymer devices
Pattern transfer and bonding in polymer materials depend on the type of polymer. Soft
lithography is usually employed for pattern transfer in elastomers like PDMS while hot
embossing, injection molding and laser ablation are commonly used for thermoplastics.
Activation of the polymer surface by plasma oxidation is the most common method for enabling
bonding in elastomers, while thermal and solvent bonding are commonly employed for
thermoplastics.

Soft lithography has become popular because the fabrication process is simple.23 Though PDMS
is the most commonly used polymer with soft lithography, other materials including
polyurethane and thermally curable epoxy have also been used.24,25 In the process of soft
lithography a prepolymer mixture is poured on the master mold (fabricated by photolithography
or e-beam lithography) with positive features, and cured. The patterned polymer replica
produced is then detached from the master mold and bonded to another polymer piece, glass or
silicon, to form a complete device. One drawback of this technique is that photolithography is
still required for the production of the master mold.26

For hot embossing, a master template with positive features is pressed against a polymer piece at
a defined temperature and time, either with an oven or a hydraulic press at temperatures above
the glass transition temperature of the material. This imprints the structure from the template
onto the plastic material.27 In injection molding, which is the preferred commercial method
because of its good reproducibility,28 molten polymer is injected into a molding machine
containing a patterned mold insert capable of withstanding high temperatures and pressures. The
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replica formed is removed after cooling.29,30 In laser ablation, a high-power laser is used to create
features in the thermoplastic by the removal of materials according to a programmed pattern.31,32
While the method is fast and patterns can be easily changed through the control software, not
many polymers are suitable for this process and the surface chemistry obtained is different from
the native polymer.30

Thermoplastics can be bonded using heat, solvent or adhesives. Thermal bonding is achieved by
pressing two cleaned substrates together and heating the unit above the glass transition
temperature of the polymer in an oven or hot press. Bonding occurs as a result of mixing of the
polymer chains between the two surfaces.33 This process is simple; however, microchannel
deformation can occur and the bond strength, though good, is weaker than that achieved by
solvent bonding.34,35 Solvent bonding is accomplished by exposing the substrate surfaces to a
solvent that is capable of dissolving the polymer. A variety of organic solvents can be used
depending on the polymer type. To prevent the solvents from dissolving the polymers and
deforming channels, sacrificial layers made from wax36,37 or ice38 can be used. Modification of
the polymer surface by plasma oxidation has also been shown to improve bond strength in
thermoplastics.39 Adhesive bonding is a simple method of sealing thermoplastic devices.33 The
approach is similar to that of solvent bonding except that it employs glue, epoxies or acrylates.
The main limitation of this technique is channel clogging caused by the flow of adhesives into
the channel.40
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1.1.4 Limits of miniaturized systems
Microfluidic channels have small overall volumes, laminar flow and a large surface-to-volume
ratio. Dimensions of a typical separation channel in microchip electrophoresis (µCE) are: 50 µm
width, 15 µm height and 5 cm length for a volume of 37.5 nL. Flow in these devices is normally
nonturbulent due to low Reynold’s number resulting in diffusion-limited mixing, which is a
slower process than that obtained with turbulent flow. Therefore, improved mixing is usually
achieved by the use of complex geometries or the integration of micromixers.41 These small
channel sizes have a high surface-to-volume ratio, leading to nonspecific adsorption and surface
fouling. Microfluidic devices also have lower separation efficiencies than conventional
techniques which separate samples better with longer separation columns.42 Additionally, the
optical pathlength for a channel height of about 15 µm is shorter than for traditional separation
columns, resulting in reduced detection sensitivities.43

1.2 MICROCHIP ELECTROPHORESIS
1.2.1 Introduction
Electrophoresis is a powerful liquid-phase separation technique that can be used to separate a
diverse range of analytes. Microchip electrophoresis, first demonstrated in the early 1990s, is one
of the best miniaturized separation techniques because it is fast, has good resolution, and does
not need moving parts.44,

45

Unlike with traditional capillary electrophoresis instrumentation,

which consists of one or more discrete capillaries, many different fluidic channels can be
patterned on a microfluidic device for integration and throughput.45 The use of microscale
channels reduces the effects of Joule heating, facilitating the use of higher voltages for more
efficient separations.46 Advantages of electrophoretic methods include high efficiency and speed,
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and low sample consumption. However, as indicated above limitations are concentration
sensitivity, constrained by the injection of small volumes, and the short optical pathlength.47

1.2.2 Theory
In both conventional capillary electrophoresis and µCE, analytes are separated according to their
electrophoretic mobilities.48 When an electric field is applied to a buffer in a capillary the
analytes acquire different velocities described by equation 1.1.
ν = µeE

(1.1)

where ν is the migration velocity (m s-1), µe is the electrophoretic mobility (m2 V-1s-l) and E is the
electric field. The electrophoretic mobility is given by
µe = q/6πηr

(1.2)

where q is the charge on the molecule, η is the viscosity of the solution and r is the Stokes radius
of the molecule. Differences in analyte charge and size will therefore affect electrophoretic
mobility, with a faster mobility achieved for smaller analytes with higher charge. 45

Electroosmotic flow (EOF) is generated from capillary or microchannel walls during
electrophoresis. When voltage is applied to a buffer solution in contact with a charged surface,
an electrical double layer of charge (an inner rigid or Stern Layer and an outer diffuse layer) is
created as oppositely charged ions from the buffer are attracted to the surface charges.49 An
electrokinetic potential known as the Zeta potential is formed in this double layer and its
potential decreases with distance from the capillary wall. Figure 1.1 depicts the formation of
such a layer on a negatively charged wall.
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Figure 1.1. Direction of EOF of a buffer solution in a negatively charged channel.

This double layer is the basis for EOF, where an applied voltage causes cations within the
loosely bound diffuse layer to move towards the cathode, dragging the bulk solution along. The
velocity of this flow is given by:
νeof = (εoεζ/4πη)E

(1.3)

where, εo is the dielectric constant of vacuum, ε is the dielectric constant of the buffer and ζ is the
zeta potential. Electroosmotic mobility (µeof) is therefore εoεζ/4πη.50 Since both electroosmosis
and electrophoresis occur concurrently,51 the overall velocity (νnet) of an analyte is dictated by
the combination of its electrophoretic and electroosmotic mobilities:45, 50
νnet = (µep + µeof) E

(1.4)

Factors such as pH, electric field, surfactants, organic solvents and wall coatings that affect the
zeta potential, dielectric constant and viscosity will also affect EOF.48

EOF has both advantages and disadvantages. A disadvantage of EOF is that its reproducibility
from run to run is affected by changes in capillary surface properties, for example caused by
adsorption.50,51 However, EOF has many advantages including the fact that it can be used to
9

control the overall migration speed, making it possible for the simultaneous separation of anions,
cations and neutral molecules. When electroosmosis and electrophoresis are in opposite
directions and EOF is strong (νEOF > νe) migration by EOF will dominate. Additionally, since the
flow profile of EOF is flatter than the parabolic or laminar flow profiles generated by hydraulic
pressure (Figure 1.2), broadening of the analyte zone is minimized resulting in improved
separation efficiencies.50

Figure 1.2. Flow profiles generated by (a) EOF, and (b) pressure.

1.2.3 Operation of µCE devices
The basic operations performed in µCE are sample injection, separation and detection. The
fundamentals of these basic steps employed in microdevices are discussed below.
1.2.3.1 Injection
Reproducible introduction of sample into the separation channel is an essential requirement for
analysis in microfluidic devices.52 The sample plug must be distinct because sample leaking into
the separation channel after injection will cause band-broadening and result in poor separation
efficiency.53,54 Many configurations or channel geometries have been used to facilitate injection

10

in microdevices. The most common configurations are the simple cross (Figure 1.3A) and offset
T (Figure 1.3B). The offset T configuration is used to inject a larger volume of sample than
simple cross devices.55 Two methods commonly used for sample introduction in microdevices
are electrokinetic and hydrodynamic injection, with electrokinetic being the most common
method. With conventional CE hydrodynamic injection is more widely used.56

Electrokinetic injection involves the manipulation of voltages between the injection and
separation channels such that a defined sample plug at the intersection between these channels is
moved into the separation channel. The popularity of this method relies on its simplicity and
flexibility since no added equipment is needed.54,57 However, this technique is prone to bias in
favor of analytes with higher mobility, resulting in reduced loading of low-mobility
components.52,58 Another problem sometimes encountered is the leakage of sample into the
separation channel, which can cause peak tailing and decreased resolution.

Figure 1.3. Schematic designs for µCE. (a) Simple cross. (b) Offset T.
11

Samples can be injected electrokinetically by either the “float”, “pinched” or “gated” techniques.
The float technique was the original approach employed for sample injection in microdevices.59
In this technique sample is injected by application of voltage only between the sample and waste
reservoirs (Fig. 1.3) while the other two reservoirs are floated. For separation, the sample and
waste reservoirs are floated while voltage is applied between the buffer and separation waste
reservoirs. Because this technique was prone to sample leakage into the separation channel,
resulting in poor resolution and tailing, the pinched and gated modes were explored.52, 59

Pinched injection is the major technique used because it delivers discrete sample plugs into the
separation channel. For pinched injection, voltage is applied to the sample waste reservoir while
the sample reservoir as well as the reservoirs at each end of the separation channel are grounded
(Figure 1.4A). This ensures that the sample does not migrate into the cross channel as it moves
through the intersection to the waste reservoir. Then, application of voltage across the separation
channel (Figure 1.4B) transfers the sample from the intersection into the separation channel for
analysis. Sample leakage into the separation channel is prevented by simultaneous application of
voltages to the sample and sample waste reservoirs to pull back excess sample towards these
reservoirs.55
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Figure 1.4. Schematic representation of “pinched” injection. (a) Injection. (b) Separation.

In gated injection the sample and buffer reservoirs in Figure 1.3 are interchanged such that with
the application of voltage the sample flows in an L-pattern from the sample reservoir to the waste
reservoir (Fig. 1.5A). Simultaneously, buffer from the buffer reservoir flows to the separation
waste to minimize sample leakage. Injection of sample is performed by momentarily turning off
the voltage between the buffer and separation waste reservoirs to allow a sample plug to be
transferred into the separation channel (Fig. 1.5B). The voltage set-up is then switched back to
the original mode for separation (Fig. 1.5C).60 The volume of sample injected depends on the
injection time, which is advantageous in that the injected volume of sample can be varied from
run to run, unlike in “pinched” injection.53 However, sample mobility bias in this method is
greater than for pinched injection.61

13

Figure 1.5. Schematic representation of “gated” injection. a) Sample loading. b) Injection of
sample into separation channel. c) Separation of sample.
Hydrodynamic injection can be accomplished by the application of pressure or vacuum. The
main advantage offered by hydrodynamic injection is the lack of injection bias commonly
encountered with electrokinetic injection, which is the main reason it is commonly used in
conventional capillary electrophoresis. However, hydrodynamic injection in microfluidic
systems requires a more complex set-up, which may include external or integrated pumps such
as ones involving membranes.52,58 Various mechanisms that have been used for hydrodynamic
injection include hydrostatic pressure, from unequal filling heights for the sample and sample
waste reservoirs,62 syringe pumps52 and pneumatic valves.61

1.2.3.2 µCE modes
All of the electrophoresis modes described here that have been demonstrated in microfluidic
devices were originally developed for regular capillary electrophoresis. Free solution
14

electrophoresis is the most common method and is discussed in Section 1.2.2 above. In addition
to free solution electrophoresis, other variants are also employed for specific purposes as
discussed below.

Gel electrophoresis uses a sieving matrix to enhance fractionation.

The resolution and

reproducibility of this method is better than for free solution electrophoresis.63 The most
common matrix employed is polyacrylamide, usually in the linear or cross-linked form.64 Linear
polyacrylamide is easy to use and can be replaced after each run for lower viscosity
formulations, which improves run-to-run reproducibility. However, linear polyacrylamide has
lower resolving power than cross-linked polyacrylamide.65 The main difficulty encountered with
in situ polymerization of cross-linked polyacrylamide is precise control of conditions to avoid
polymerization in other locations of the channel.66 Addition of SDS to the matrix can enable
size-based protein separation.67

A hybrid of chromatography and electrophoresis, capillary electrochromatography (CEC) has a
mobile phase moved by EOF, with separation based on both electrophoretic mobility and
interaction with a chromatographic stationary phase. Compared to free solution electrophoresis, a
better separation efficiency is obtained for both charged and uncharged species since the
stationary phases used provide additional interaction for uncharged molecules.68,69 CEC benefits
from reduced zone broadening compared to HPLC because of plug-like flow.68,70 CEC is well
suited for miniaturized formats, and the designs of the microfluidic devices used are similar to
those for µCE. Jacobson et al.71 first reported CEC in microchips using an open channel coated
with octadecylsilane as stationary phase. Other stationary phases now used include coated silica
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beads,72 coated microfabricated column structures69,

73

and polymer monoliths.74 With porous

polymer monoliths different monomers can be selected to achieve a specific type of separation.75
For example, EOF can be tailored by copolymerization of a negatively or positively charged
monomer,74,76 although even neutral monoliths can exhibit EOF despite the absence of fixed
charges.77

1.2.3.3 Detection
Various detection methods have been employed in microfluidic systems including optical and
electrochemical detection, and mass spectrometry. Some of the methods require conjugation of
the analyte to enable detection while other methods are label-free.

Optical detection methods are most commonly employed in microdevices because they have low
detection limits, are isolated from the fluid and can be used to monitor a wide variety of
compounds.78 Several approaches to optical detection are currently being implemented in
microfluidic devices; these are label-based (such as fluorescence and chemiluminescence) or
label free (such as UV absorbance).

Laser-induced fluorescence is the most frequently used optical method in microfluidic systems
because of its low detection limits.79 However, samples that do not fluoresce naturally need to be
derivatized, often with variants of either fluorescein or rhodamine, which fluoresce in the green
and red regions of the spectrum, respectively.79 In many instances the optics for detection in
microfluidics are external to the chip itself. For LIF a laser is used for excitation and a
photomultiplier or CCD is used for detection (Fig. 1.6.).80, 81 While label-based methods require
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time consuming sample derivatization, the detection limits of LIF are typically better than for
label-free methods.

Figure 1.6. Schematic of a laser-induced fluorescence system for µCE detection.

Chemiluminescence (CL) is based on the production of light through a chemical reaction or
when a reaction product transfers its energy to another molecule that then emits light.82 CL
detection has the advantage of not requiring an excitation source that raises background;
however, very sensitive detectors are required.

UV absorbance is a label-free method commonly used in HPLC and electrophoresis systems.
However, its sensitivity is reduced by the short optical path lengths commonly encountered in
microfluidic channels.43 Both off- and on-chip UV absorbance formats have been shown in
17

microdevices. The off-chip format is more commonly employed because it avoids complications
of fabrication of integrated systems. In the on-chip format, a detection cell which measures
absorbance along the plane of the device is used, which increases the pathlength and results in
improved sensitivity.43

Native UV-excited fluorescence is a label-free detection method that typically entails excitation
between 210 and 325 nm.43,

83

This method, which requires a UV excitation source and a

detection system, is not commonly employed in microfluidic systems. Its sensitivity is usually
inferior to visible LIF.83 The devices used with this detection method must be transparent to UV
light; acceptable materials include quartz and fused silica, as many glass and plastic materials are
not UV transparent.43

Electrochemical detectors are increasingly being used because they can be miniaturized without
reducing sensitivity.84 Conductivity, amperometry and potentiometry are the most commonly
used electrochemical detection methods in microfluidics. Conductivity detection takes advantage
of the conductivity difference between the background electrolyte in solution and the analyte.85
Two modes have been implemented in microfluidic devices. In the contact conductivity mode,
the detection electrodes are in direct contact with fluid inside the channel.86 With contactless
conductivity, the electrodes are isolated from the solutions in the device, avoiding issues such as
electrode fouling and bubble formation.87,

88

Amperometric detection relies on the electrical

current produced from the oxidation or reduction of a species by a voltage applied between a
reference and a working electrode.89 This method is advantageous in that the electrodes can be
fabricated by photolithographic processes within the microfluidic device.90 In potentiometric
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methods the potential of an ion-selective electrode relative to a reference electrode is probed.
The resulting charge separation that occurs generates a potential between the working and
reference electrodes that depends on the type of ion and its concentration.89 As for amperometric
detection, microfabrication technologies can be used to integrate potentiometric electrodes in
microfluidic devices.91-93

Interfacing microfluidics with MS detection produces valuable data, enabling discrimination
based on small differences in mass.94,95 ESI and matrix-assisted laser desorption/ionization
(MALDI) are two ionization methods for interfacing microfluidic chips with MS. ESI-MS76, 96, 97
is the more common approach for coupling microdevices to MS, and these systems are simpler
but less suitable for parallel analysis, compared to MALDI-MS.95

1.3 ANALYSIS OF CANCER BIOMARKERS
1.3.1 Introduction
Biomarkers are measurable molecules that can indicate a difference between normal and disease
states, or therapeutic response.98,99 An ideal biomarker should be easy to measure in a noninvasive manner and with high sensitivity and specificity.98 Cancer biomarkers can be obtained
from tissue samples or body fluids and play a key role in early detection and treatment.
Considerable research has focused on the discovery of cancer biomarkers in body fluids. Though
single biomarkers have been useful for screening, diagnosis and prognosis, more reliable results
are obtained with a panel of biomarkers.100 Cancer biomarkers can be proteins, nucleic acids,
peptides, carbohydrates, or other metabolites. However, all of the FDA approved biomarkers are
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proteins, and protein markers are considered to be more useful than other markers since protein
molecules directly influence molecular pathways in cells.101,102

1.3.2 Protein biomarkers
Of the numerous proteins proposed as cancer biomarkers, only those shown in Table 1.1 have
been approved by the FDA.103 Their sensitivities, specificities and threshold values are shown in
the table. The specificity of these biomarkers is reasonable (70-98%) but their sensitivity is
somewhat worse (40-96%), which is one of the reasons why better diagnosis is provided by a
combination of biomarkers. The cut off concentration (above which a positive diagnosis is made)
for most of the biomarkers is low, below 20 ng/mL. Therefore, improved sensitivity will be
obtained if the biomarkers are concentrated prior to detection. Here, I focus on five protein
biomarkers that I have studied: alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), heat
shock protein 90 (HSP90), thymidine kinase 1 (TK1), and cytochrome c.

AFP is a diagnostic marker for hepatocellular carcinoma (HCC). AFP is a 67 kDa glycoprotein
which is present in high levels in fetal sera.104 Its concentration decreases to trace levels soon
after birth; therefore, raised AFP levels in adult serum usually indicate a disease state. AFP
concentrations above 20 ng/mL are indicative of HCC, with reported sensitivity between 50 and
85%, and specificity between 70 and 90%.105 Recent studies have shown that AFP
concentrations can also be used to predict the outcome for HCC treatment. Patients with elevated
levels of AFP who were treated with sorafenib and showed >20% decrease in AFP concentration
within 8 weeks of treatment had improved survival and lowered disease progression than those
that did not show a decrease in AFP concentration.103, 106
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Table 1.1 Sensitivities and specificities for the nine FDA approved cancer biomarkers.103 (NA –
not available; SPIgR– secreted chain of polymeric immunoglobulin receptor).
Marker
Disease
Cut off
Sensitivity Specificity Reference
CEA

malignant
pleural effusion

NA

57.5%

78.6%

107

CEA

peritoneal cancer
dissemination

0.5
ng/mL

75.8%

90.8%

108

Her-2/neu

stage IV breast
cancer

15 ng/mL

40%

98%

109

Bladder Tumor
Antigen

urothelial cell
carcinoma

NA

52.8%

70%

110

Thyroglobulin

thyroid cancer
metastasis

2.3
ng/mL

74.5%

95%

111

Alpha-fetoprotein

hepatocellular
carcinoma

20 ng/mL

50%

70%

105

PSA

prostate cancer

4.0
ng/mL

46%

91%

112

CA 125

ovarian cancer

41U/mL

62%

98%

113

CA 19.9

pancreatic cancer NA

75%

80%

114

CA 15.3

breast cancer

40 U/mL

58.2%

96%

115

Leptin, prolactin,
osteopontin, and
IGF-II

ovarian cancer

NA

95%

95%

116

NA

96%

77%

117

CD98, fascin, sPIgR, lung cancer
and 14-3-3 eta
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CEA is a 180 kDa glycoprotein that is overexpressed in colorectal and other epithelial cancers,
and is also useful in predicting recurrence of these cancers.118-120 It is produced by the fetal gut
but its level decreases in adults, and it functions as a cell adhesion molecule.121 The sensitivity of
CEA in predicting peritoneal cancer at a cutoff level of 0.5 ng/mL was found to be 76% while
the specificity was 91% which is among the best of the biomarkers in Table 1.1. Apart from
epithelial tumors, CEA level is also increased in smokers, and people with pancreatitis and liver
disease.119

Another biomarker of interest is HSP90, a 90 kDa molecular chaperone that oversees the proper
folding, stability and maturation of newly formed proteins.122 Many HSP90 clients are proteins
whose mutation or overproduction promotes cancer, making HSP90 inhibition a target in cancer
therapy.123,

124

Some of these mutated client proteins have shown a greater dependence on

HSP90 than their normal counterparts,125 and within certain drug concentration limits, inhibition
of HSP90 had a greater impact on cancer cells compared to healthy cells.126 For example,
significant degradation of mutant as opposed to normal epidermal growth factor receptor, whose
overexpression has been implicated in lung cancer, was seen with the administration of an
HSP90 inhibitor.125 Therefore, although HSP90 is presently not FDA approved, its elevated
levels in many human cancer types and the depletion of client proteins by its inhibition indicate
potential utility for diagnosis and the monitoring of response to treatment.122,127

TK1 is a cytosolic enzyme that is crucial in the deoxyribonucleotide salvage pathway involved in
DNA synthesis and repair, catalyzing the phosphorylation of thymidine to its monophosphate
form.128-130 TK1 interchanges between the dimeric, low catalytic form to the tetrameric high
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catalytic form depending on the presence or absence of ATP. Each subunit is ~25.5 kDa.129 TK1
expression is closely related to cell proliferation, with low or no activity in resting cells,131 but
increased activity in the S phase coinciding with greater DNA synthesis.129 Extensive studies
have shown that TK1 is a biomarker for a variety of cancer types,132 with serum and tissue levels
correlating with the stage and aggressiveness of the cancer.128 Inefficient cell-cycle control of
TK1 by cancer cells has been implicated in the increased levels found in cancer patients.133
Diagnostic concentrations of serum TK1 have been found to be >2 pM, with sensitivities and
specificities depending on the cancer type.134 Serum TK1 levels have also been shown to be
helpful in prognostics in many cancer types including leukemia, breast, prostate and bladder
cancers, as well as small-cell and non-small-cell lung carcinomas. 130,133

Cytochrome c is a heme protein with a molecular weight of ~12 kDa that plays an important role
in electron transport during respiration and the onset of apoptosis.135,136 Though cytochrome c is
not a classic cancer biomarker, elevated levels observed in some cancer patients were found to
gradually decrease during treatment.137,138 Its usefulness is thus limited to patients known to have
cancer since elevated levels also occur in other non-malignant diseases.138

1.3.3 Detection methods
Though a lot of progress has been made in the early detection of cancer using biomarkers,
ultimate diagnosis still requires a biopsy because elevated levels of some biomarkers also
indicate other benign conditions.99 One of the challenges encountered in the application of cancer
biomarkers in clinical settings is the detection of low concentration analytes in a matrix
containing many other proteins which are usually present at much higher concentrations.103
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1.3.3.1 ELISA
The most common technique used for the detection of biomarkers is enzyme-linked
immunosorbent assay (ELISA). In this method a monoclonal antibody immobilized on a solid
surface is used to capture a specific biomarker from a biological fluid. An enzyme-conjugated or
fluorescently labeled secondary antibody is then complexed to the biomarker via a different site
from the first antibody to generate a measurable signal. This technique is commonly referred to
as sandwich ELISA because the antigen is trapped between two antibodies.100,139 This format has
good throughput and reproducibility but is not desirable for parallel detection of multiple
biomarkers.140 Further challenges with ELISA-based methods are the limited availability of high
quality antibodies and lengthy analysis times.101,141 A microarray ELISA format provides high
throughput multiplex biomarker analysis, which is advantageous for early detection of
cancer.99,100 In the microarray format hundreds of monoclonal antibodies are spotted in an
ordered manner on a surface to perform an array of assays. This platform presents a costeffective method for high throughput screening of multiple proteins.142 The microarray format,
however, is susceptible to reagent cross-reactivity resulting in errors due to reduced specificity;
therefore, its implementation in a microchip format requires complex designs to minimize these
errors.142

1.3.3.2 Proteomic methods
The availability of high-resolution MS has led to progress in proteomics143 and the detection of
protein biomarkers. Traditional proteomics methods that have been used for cancer markers
include two-dimensional polycarylamide gel electrophoresis (2D-PAGE) with MS detection,144
capillary electrophoresis-MS145 and liquid chromatography coupled to hyphenated MS.146,147
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Capillary electrophoresis is a powerful separation method and its combination with MS has been
shown to be useful for the analysis of intact proteins.145 2D-PAGE with MS detection is more
suitable for biomarker discovery than routine detection of biomarkers,144 while LC-MS/MS can
be applied to both biomarker discovery and routine detection of biomarkers.102 However, LC-MS
cannot be used for POC detection.99

1.3.3.3 Microfluidc methods
The significance of microfluidic technology for biomarker analysis in POC settings has been
demonstrated in several publications. Wang et al.148 developed a microchip sandwich ELISA
technique for POC detection of the ovarian cancer biomarker, human epididymis protein 4 (HE4)
in urine. Colorimetric detection was accomplished with a cell phone/camera, and analysis with
an integrated mobile application allowed reporting of the pixel value for each channel. The
method successfully differentiated ovarian cancer patients from the control group. An integrated
PMMA microfluidic device with a monolithic affinity column coupled to µCE was used for the
extraction and quantification of cancer biomarkers in human blood serum. The microchip was
designed with multiple reservoirs to enable automated transfer of the different fluids required for
loading, rinsing, eluting and separating the sample.149 Simultaneous detection of four biomarkers
in the serum of oral cancer patients was achieved with a microfluidic array consisting of
immobilized antibody-functionalized magnetic beads. This method detected oral cancer with a
sensitivity of 89% and a specificity of 98%.150
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1.4 SAMPLE PREPARATION METHODS
1.4.1 Overview
Conventional sample preparation methods involving filtration, extraction, enrichment and
labeling are time consuming and can lead to sample loss before analysis.151 Filtration is a sizebased method wherein small molecule contaminants are separated from the sample with the use
of filter membranes as in ultrafiltration and gel filtration. Alternatively, centrifugation or dialysis
can be used. Classical sample extraction techniques are liquid-liquid extraction (LLE) or solvent
extraction and solid phase extraction (SPE). In LLE, a separation funnel is used to transfer a
compound from one solvent into a second immiscible solvent. SPE, on the other hand, employs
the adsorptive power of a stationary phase to retain components from solution. The most
common methods for concentrating samples involve filtration with a membrane, SPE and
dialysis. Stacking and focusing techniques are also commonly used for preconcentration prior to
electrophoresis. For sample labeling, the sample is mixed with an appropriate dye and incubated
for a certain period of time, usually at room temperature, before analysis. Though the integration
of these sample preparation methods in microfluidic devices can be challenging, significant
progress has been made.152 Advantages of microfluidic sample preparation include automation
and integration, which facilitate assays such as for point-of-care usage.153

1.4.2 Extraction and purification
Solid phase extraction is a useful purification and enrichment method wherein analytes are first
retained on a solid support and then are subsequently eluted in a concentrated form.154 SPE is a
chromatographic technique which avoids many of the problems encountered in liquid-liquid
extraction such as incomplete phase separations and reduced sample recoveries.155 In this
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technique, which is typically carried out in a cartridge, the sample is loaded on a stationary phase
and the unattached sample is washed away. A suitable solvent is then used to elute the extracted
analyte.155 Implementation of this procedure in microfluidic systems is facilitated by the fact that
it can be integrated with other processes like thermal cycling, separation and detection.156 The
most common SPE modes in microfluidics are reversed-phase, which works for non-polar to
moderately polar compounds, and affinity, which provides greater specificity via interaction
between target analyte and a complementary compound such as an antibody bound on the solid
phase.

In reversed-phase extraction the stationary phase is non-polar while the analyte is dissolved in a
polar matrix. Less polar analytes are attracted to the stationary phase due to chemical similarities.
Elution of the sorbed analyte is achieved through a non-polar solvent which is capable of
displacing the analyte from the stationary phase.157 Silica-based columns (beads, particles,
porous silica sol-gel, and bead/sol-gel hybrids) are the most common supports used for reversedphase SPE and they have been shown to be both reproducible and reliable.158 The hydrophilic
silanol groups at the surface of the silica are generally coupled to hydrophobic alkyl or aryl
functional groups by reaction with silanes, with C8 and C18 being some of the most widely used
coatings.159, 160 The use of monolithic columns is increasing, especially in the microchip format,
because they can be easily prepared by UV polymerization without a need for forming retaining
structures like frits.76, 161 In addition, the porosity and surface area of monoliths can be tuned by
varying the monomer and porogen composition.74 Appropriate hydrophobicity for reversedphase SPE is provided by monoliths made of butyl-, lauryl-, octadecyl-, or 2-hydroxyethyl
methacrylates.11, 154, 162, 163
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Affinity extraction techniques which are based on the strong interaction between an analyte and a
receptor attached to the column are highly specific. In this method a ligand with high affinity for
the analyte of interest is immobilized on the stationary phase and the sample is passed through
the column. Molecular recognition of the analyte by the ligand then enables its extraction while
the other components are not retained. Elution of the sample is achieved by changing the pH,
temperature or polarity of the buffer, or by the use of a specific component which binds to the
ligand more strongly than the analyte.164 Affinity extraction is frequently used for sample
pretreatment to isolate a specific component before analysis. This technique also purifies and
concentrates that component. A wide variety of ligands have been implemented in both
conventional and microfluidic formats. Anti-fluorescein isothiocyanate (FITC) was immobilized
on monoliths in PMMA microdevices and used to selectively extract FITC-tagged proteins,
followed by elution and µCE separation.165 Biotinylated PCR products were selectively extracted
on a streptavidin-modified bed fabricated in a PMMA microdevice; the purified material was
subsequently eluted by thermal denaturation and analyzed by µCE.166 Aptamers, which are short
nucleic acid sequences that bind to target molecules with high specificity, are alternatives to
antibody-based extraction. A PDMS-glass multilayer microfluidic device packed with aptamerfunctionalized microbeads was used to selectivity extract and concentrate arginine vasopressin,
with its temperature-dependent binding and release controlled by an integrated microheater and
temperature sensor.167 The binding of target nucleic acid sequences to their complementary
immobilized probe nucleic acid molecules has also been investigated in microfluidic devices,
particularly for DNA microarrays.168
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1.4.3 Preconcentration
Preconcentration is frequently employed in sample analysis for the determination of low
concentration analytes.169 The simplest preconcentration method is filtration where the sample is
passed through a membrane, usually made of cellulose, and the components separate on the basis
of size. Another technique, LLE, is a straightforward method of sample preconcentration which
requires two immiscible solvents. However, a large amount of solvent is required in this
technique and it is gradually being replaced by newer variants such as homogeneous LLE and
dispersive

liquid-liquid

microextraction.

Other

preconcentration

techniques

include

chromatography-based SPE, discussed in Section 1.4.2, and methods based on electrophoretic
mobility, like stacking or isotachophoresis. The volume of loaded sample in chromatographybased methods does not depend on the volume of the column, so large volumes can be loaded for
improved enrichment.170 Samples can be concentrated prior to (off-line) or after (on-line)
injection. The on-line format is commonly used because it has a higher concentration efficiency
than the off-line format.171 Various on-line sample preconcentration techniques, utilizing analyte
characteristics such as charge, affinity, mobility and size, have been applied to overcome the
limited concentration detectability resulting from the short optical path lengths in microfluidic
channels. An additional benefit of concentrating samples prior to analysis is improved detection
of low concentration analytes typically encountered in real-world samples.172

In isotachophoresis (ITP) a leading electrolyte (the fastest moving ion), sample and trailing
electrolyte (the slowest moving ion) are injected in that order into a separation column. The
sample components separate according to their mobilities, with the fastest ion directly behind the
leading electrolyte and the slowest near the trailing electrolyte, and a constant speed for all ions
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in the sample zone is maintained. Advantages of ITP are large preconcentration factors and ease
of coupling to separation techniques such as capillary zone electrophoresis, isoelectric focusing
and gel electrophoresis.173 However, its execution is complicated by the fact that it requires
rigorous selection of buffers and mobility markers for each analyte.174 For microchip ITP
determination of bacterial urinary tract infections, 16S rRNA was monitored in bacterial lysates
obtained from patient urine samples using molecular beacons. The combination of extraction,
focusing, and detection of 16S rRNA was realized in a single step and clinically significant
concentrations of E. coli were detected.175

Compared to free solution techniques, enrichment based on exclusion methods such as
nanoporous filters generally offers a simpler analysis setup and can be employed in both
electrophoretic and chromatographic methods. The filters, usually nanoporous monoliths or
membranes, are integrated into the column and their properties enable selective trapping of
certain components.151 In the use of membranes for preconcentration analytes are selectively
transported across the membrane.176 Most of the membranes used in electrophoretic methods are
anionic enabling ion-selectivity. With the application of voltage across these charged membranes
analytes of a specific charge are concentrated on one side of the membrane and subsequently
analyzed. Hydrogel membranes made from acrylic monomers can act as either neutral or charged
nanoporous filters whose pore size and mechanical properties can be controlled by varying the
polymerization conditions. Hatch et al.177 integrated two neutral acrylic polymer hydrogel
membranes in a glass device, one for size-based preconcentration and the other as a separation
matrix for gel electrophoresis. Negatively charged acrylamide membranes can be formed by
addition of an ionizable co-monomer, such as 2-acrylamido-2-methylpropanesulfonic acid
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(AMPS), enabling the membrane to be ion-selective.178 Chun et al.178 showed preconcentration
of anions with an ion-conductive membrane made entirely of crosslinked AMPS in glass
microchips. Other membranes that have been employed include polycarbonate, titania, and
Nafion. Polycarbonate nanopore membranes were integrated in PDMS microchips and used to
concentrate labeled serum albumin.179 Titania membranes fabricated at the intersection of two
fluidic channels on a microfluidic device were used to electrokinetically enrich 2,7dichlorofluorescein.180 Proteins were also concentrated in a PDMS-glass microfluidic device
having an integrated Nafion strip.181

1.4.4 Fluorescent labeling
Many samples do not fluoresce naturally and have to be derivatized to benefit from the low
limits of detection of LIF. The fluorescent dyes used are usually small organic molecules with
reactive groups that attach to specific sites on the analyte.182 For labeling, a sample is mixed with
the fluorescent dye and left to react between 1 – 24 h at room temperature.183,184 The
unconjugated dye is then removed before analysis.183 Efficient labeling is obtained with original
sample concentrations between 1 – 10 mg/mL,185 though lower concentrations could be equally
labeled with higher dye-to-sample molar ratios. One disadvantage of labeling samples at high
concentration is that not all of the sample can be used and the rest will be wasted.

1.4.4.1 On-chip labeling
On-chip labeling was developed to address some of the issues of conventional labeling such as
lengthy label times and the necessity to label high concentrations of samples. In on-chip labeling
lower sample concentrations are possible and the labeled samples are used immediately.
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Moreover, there is a significant reduction in the time required for labeling.

In addition,

integration of labeling into microfluidic devices increases automation. On-chip labeling has been
achieved both in pre-column and post-column formats. Pre-column labeling was initially shown
in a glass microchip for on-chip labeling of amino acids with subsequent µCE and LIF
detection.186 To carry out parallel analysis of multiple unlabeled samples, a multilayer PMMA
microfluidic device with integrated on-chip labeling and electrophoretic separation was
demonstrated wherein one fluorescent label reservoir allowed parallel labeling and analysis of up
to eight samples in different channels.187 A long serpentine reaction channel was employed for
online derivatization of reduced glutathione with ThioGlo-1. The system integrated
derivatization, injection, separation and detection, enabling the study of glutathione reductase
kinetics by continuously monitoring the concentration of the generated reduced glutathione.188

Post-column methods require the placement of an additional connection after separation but
before detection. A cross design glass microchip with a post-column reactor positioned between
the separation channel and the detection point was fabricated and used for derivatization of
separated amino acids.189 A similar post-column setup was employed to continuously monitor
the on-chip release of neurotransmitters from immobilized PC 12 cells in a multilayer PDMSglass device incorporating a cell reactor, continuous flow sampling and electrophoresis, with
post-separation derivatization for fluorescent detection.190 Though on-chip labeling provides
automation and faster sample derivatization compared to off-chip labeling a major limitation is
the presence of unreacted dye which in high concentration could conceal some analyte peaks.
Separation of unreacted dye from sample prior to detection is therefore necessary. Another
limitation is that the dynamic labeling usually employed has a lower labeling efficiency for more
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dilute samples due to the elimination of incubation time. This could be alleviated by the
incorporation of micromixers or by use of a solid support which allows more interaction between
the sample and fluorescent dyes.

1.4.5 Integration
Integration is one of the key advantages of miniaturization,191 and can facilitate assays such as
for point-of-care usage.153 Indeed, the objective of lab-on-a-chip (LOC) systems is to integrate
all laboratory processes into a single device so that sample pre-treatment, chemical reaction,
separation, detection and data analysis operations can be carried out in an automated manner.192
Though important progress toward this goal has been made, most microfluidic systems typically
perform only one or a few select steps on-chip.193 The integration of complex functions on-chip
can limit sample loss, reduce analysis time, and enable new detection methods for microfluidic
analyses, as an example.152,194 The extent of integration can be anywhere between a disposable
chip in external equipment to complete integration of all laboratory functions.195 Components
such as pumps, valves and mixers, which enable functions such as sample preparation,
separation, etc., are integral to creating LOC systems. Remaining challenges in making fully
integrated LOC systems are the complexity of combining several different components in a
single device196 and interfacing with the macroscopic world.197 Some examples of integrated
microfluidic systems are discussed below.

Microfluidic systems that integrate sample preparation methods with separation offer automated
analysis. Magnetic bead based immunoassays for immunoglobulin and prostate specific antigen
were demonstrated in a multilayer PDMS-glass microfluidic device. In this technique, automated
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parallel loading of capture antibody, wash buffer, antigen and magnetic bead-coated secondary
antibody into patterned reaction wells was performed with the aid of integrated valves and
pumps.198 Both reversed-phase and affinity SPE modules have been integrated into
microdevices. C18-coated magnetic particles have been used for in-line SPE-µCE to analyze
mixtures of parabens and fluorescent dyes. The magnetic particles were trapped at the
intersection of an offset-T microchip, and an additional side channel was connected to a syringe
pump for elution.199 An integrated PMMA microfluidic device with a monolithic affinity column
coupled to µCE was used for the extraction and quantification of cancer biomarkers in human
blood serum. The chip was designed with multiple reservoirs to enable uninterrupted movement
of the different fluids required for loading, rinsing, eluting and separating the sample.149
Immunoglobulin E and nuclear factor-κB were extracted and concentrated with an aptamerfunctionalized size-exclusion membrane in an integrated glass microfluidic device that also
enabled mixing and buffer exchange. The samples were eluted from the preconcentration
membrane directly into a separation channel for gel electrophoresis and LIF detection.200 Apart
from increasing the level of automation, integration of sample preparation reduces cross
contamination and decreases sample loss which occurs when transferring off-chip prepared
samples to microdevices. However, a major difficulty in integration of sample preparation
methods is coupling with analysis in a manner that does not decrease separation efficiency.

Though many advantages of integrated microfluidic systems have been demonstrated, as
discussed above, they also have some limitations. The main disadvantage in integrated systems is
the increase in complexity of design and analysis. For example, stacking techniques are
commonly used to couple sample preconcentration with µCE because of their compatibility.
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However, the execution of these techniques often requires complicated designs which render
separation very challenging. In addition, the integration of components such as valves and pumps
for efficient fluid manipulation requires complicated fabrication and operation processes. To
address these challenges components with low levels of fabrication complexity should be
integrated in microdevices and used to simultaneously perform a variety of sample preparation
techniques such as analyte extraction, purification, concentration and derivatization.

1.5 OVERVIEW OF DISSERTATION
The analysis of specific analytes in complex biological samples requires purification and
concentration of the desired analyte for improved sensitivity as discussed in Section 1.4. LIF
detection offers low detection limits but conjugation with fluorescence dyes is required for
samples to be detected by LIF. Most sample preparation methods are time consuming; for
example, conventional sample labeling typically requires up to 24 h. Integration of these
processes on-chip reduces the time required for overall analysis and improves the level of assay
automation. In my dissertation, I describe efforts to develop new approaches for the integration
of sample pretreatment with µCE. A brief overview of microfluidic materials, fabrication
techniques, µCE and sample preparation methods has been given in this chapter.

In Chapter 2, I present protocols for the fabrication of polymeric microfluidic devices and
affinity columns. I have adapted fabrication methods for hot embossing and thermal bonding
that were developed by previous members of Prof. Woolley’s research group. Affinity columns
were prepared in these devices by in situ photopolymerization and used for protein extraction.
Monomers used for the preparation of affinity columns had reactive epoxide groups which
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allowed for functionalization with antibodies so that specific proteins could be extracted from a
complex mixture. I also present protocols for fluorescent labeling of proteins and µCE.
Experiments on the extraction of HSP90 with an anti-HSP90 functionalized column show
specificity towards HSP90.

Chapter 3 focuses on the in situ preparation of ion-permeable membranes for on-chip
preconcentration of proteins prior to µCE.

The negatively charged membrane made from

acrylamide, N,N’-methylene-bisacrylamide and 2-(acrylamido)-2-methylpropanesulfonate was
photopolymerized near the injection intersection. Proteins excluded from this membrane based
on both size and charge concentrated at the injection intersection and were subsequently
separated by µCE. Forty-fold enrichment of BSA was achieved with 4 min of preconcentration
while >10-fold enrichment was obtained for the biomarkers AFP and HSP90 with just 1 min of
preconcentration.

In Chapter 4, I demonstrate the use of monolithic columns for on-chip preconcentration,
fluorescence labeling and purification. Sample enrichment by reversed-phase SPE was realized
with a butyl methacrylate monolith fabricated in cyclic olefin copolymer microdevices. Samples
retained on the monolithic column were labeled with either Alexa Fluor 488 or Chromeo P503,
and excess dye was rinsed off the column before elution. Application of this technique to HSP90
samples showed a linear relationship between eluted peak areas and sample concentration. This
proves that a calibration curve can be obtained and used for quantification of analytes.
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Conclusions reached from my work on the extraction of labeled proteins from affinity columns,
preconcentration of proteins prior to µCE and on-chip extraction, preconcentration and
derivatization of proteins are discussed in Chapter 5. Future work on the coupling of affinity with
reversed phase columns for on-chip protein extraction, digestion, preconcentration, labeling and
µCE with either LIF or MS detection is also discussed in Chapter 5.
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2. INTEGRATED AFFINITY AND ELECTROPHORESIS SYSTEMS FOR
BIOMARKER ANALYSIS *

2.1 INTRODUCTION
Biomarkers can be used in non-invasive early stage disease detection and in assessing patient
response to treatments.1 Present methods for biomarker detection, in prostate cancer for example,
are neither sensitive nor specific enough to enable early stage detection,2 such that improvements
are needed. A promising route to probing trace target analytes in complex mixtures entails
integrating components capable of performing sample preparation, separation, and detection into
a single device.3 Affinity columns have strong potential to provide selective analysis of desired
components in a complex matrix.4,
chromatographic assays;6,

7

5

Monolithic supports are an emerging method for

importantly, these columns can easily be prepared in microfluidic

devices by in-situ photopolymerization.8 Integration of affinity preparation with miniaturized
separation offers the advantages of sample extraction and preconcentration coupled with the
portability, speed, automation, and reduction of sample volume9, 10 provided by methods such as
microchip electrophoresis (µ-CE).

Here I describe the fabrication of poly(methyl methacrylate) microfluidic devices by the
processes of photolithography, hot embossing and thermal bonding and demonstrate an approach
for the preparation and application of affinity columns in these devices. The use of monomers
with reactive epoxide groups allowed for direct functionalization with antibodies,11-14 which is
more straightforward than a multistep process. Application of these columns to biomarker
* This Chapter is modified from Chapter 18 in: Methods in Molecular Biology: Clinical Applications of Capillary

Electrophoresis, Nge, P. N.; Pagaduan, J. V.; Yang, W.; Woolley, A. T., Vol. 919, Phillips, T. M.; Kalish, H., Eds.;
pp 189-201. Copyright Humana Press, 2013
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analysis has multiple requirements. The biomarkers need to be labeled to enable laser-induced
fluorescence detection. Biomarkers must be bound to their corresponding antibodies on the
column followed by washing to remove unwanted low-affinity components. Captured
biomarkers are eluted into a µ-CE system. These integrated devices offer efficient sample
pretreatment and preconcentration. Simultaneous quantification of multiple biomarkers in
complex mixtures such as blood serum can also be carried out with more complex device
designs.

2.2 MATERIALS
2.2.1 PMMA device fabrication
A silicon template was prepared by the photolithographic procedure shown in Figure 2.1.
Briefly, a thermally oxidized silicon <100> wafer was coated with photoresist and exposed to
UV radiation. Silicon wafers cleave according to their crystalline orientation; to obtain square
templates when the wafer is cleaved, silicon <100> is preferred since it cleaves at 90° angles.
The wafer was developed to remove exposed photoresist and then etched in 10% buffered HF
solution to remove the oxide layer. This was followed by wet etching in 40% aqueous KOH
solution to yield raised channel features of ~15 µm height.15 PMMA sheets (1.5- and 3-mm
thickness) for device fabrication were obtained from Cyro Industries, Rockaway, NJ, USA. The
thinner layer (1.5 mm) facilitates embossing of the pattern from a silicon template while the
thicker layer (3.0 mm) used for the cover plate enables a larger volume (up to 20 μL) of solution
to fit into the reservoir. This ensures that solution does not easily evaporate away during the
analysis process. Other necessary materials include glass microscope slides (75 mm × 50 mm × 1
mm), C-clamps, acetone, isopropyl alcohol (IPA), a laser cutter (Universal Laser Systems,
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Scottsdale, AZ, USA), canned compressed gas for dust removal (GUST, Quarryville, PA, USA),
copper plates, and a precision convection oven (Thermo Scientific, Asheville, NC, USA).

Figure 2.1. Photolithographic procedure for the fabrication of a silicon template.
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2.2.2 Affinity columns
Glycidyl methacrylate (GMA, 97%), ethylene glycol dimethacrylate (EGDMA, 98%), 2,2dimethoxy-2-phenylacetophenone (DMPA, 98%), 1-dodecanol (98%), and cyclohexanol were
obtained from Sigma-Aldrich, (St Louis, MO, USA). Tween 20 was from Mallinckrodt Baker
(Paris, KY, USA). Borate buffer (0.1 M, pH 8.6) was prepared as follows: 3.81 g (10 mmol) of
sodium tetraborate decahydrate was dissolved in 100 mL water in one flask and 0.62 g (10
mmol) of boric acid was dissolved in 100 mL water in another flask. The boric acid solution was
added to the tetraborate solution until pH 8.6 was reached. Tris buffer (0.1 M) was prepared as
follows: 0.65 g (5.4 mmol) Tris base and 0.72 g (4.6 mmol) Tris-HCl was weighed, transferred
to a 100 mL volumetric flask containing ~20 mL water and mixed until the solid dissolved
completely. Water was then added up to the 100 mL mark. The solution was stored at 4 °C.
Carbonate buffer (0.1 M, pH 9.3) was prepared as follows: 0.69 g (8.1 mmol) sodium
bicarbonate and 0.20 g (1.9 mmol) anhydrous sodium carbonate was weighed, transferred to a
100 mL volumetric flask containing ~20 mL water and mixed until the solid dissolved
completely. Water was added up to the 100 mL mark and the buffer was stored at 4 °C.
Monoclonal anti-AFP antibody in phosphate buffered saline (PBS, pH 7.2) was from SigmaAldrich while monoclonal anti-HSP90 in PBS pH 7.2, containing 50% glycerol and 0.09%
sodium azide was from Stressgen (Ann Arbor, MI, USA). Other materials included 1.5 dram
glass vials, a syringe pump (Harvard Apparatus, Holliston, MA, USA), a UV lamp (SunRay
from Uvitron International, West Springfield, MA, USA), a photomask and black electrical tape.
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2.2.3 Biomarker analysis
Carbonate buffer (0.1 M, pH 9.3) was prepared as in Section 2.2.2, and 0.1 M phosphate buffer,
pH 7.0 was prepared as follows: ~20 mL water was added to a 100 mL volumetric flask. 0.52 g
(3.8 mmol) monosodium phosphate monohydrate and 0.88 g (6.2 mmol) anhydrous disodium
phosphate was weighed, transferred to the flask and mixed until the solid dissolved completely.
Water was added up to the 100 mL mark and the buffer was stored at 4 °C. This buffer was made
into PBS by adding 0.88 g (15 mmol) NaCl once the flask was filled to the mark. Amicon Ultra0.5 centrifugal filters (30 kDa MWCO) were from Millipore (Billerica, MA). AFP (1.75 mg/mL
in 0.1 M PBS pH 7.4, containing 15 mM sodium azide) was obtained from Lee Biosolutions (St.
Louis, MO). The AFP buffer was exchanged with PBS, pH 7.2 - 7.4 using an Amicon Ultra-0.5
centrifugal filter. This step is essential because buffers containing primary amines such as Tris or
buffers containing sodium azide interfere with the labeling process since they compete for
conjugation with the amine-reactive dye. It is therefore important to exchange such buffers for
nonreactive ones like PBS, carbonate or borate. This buffer exchange process also concentrates
the sample to ~2 mg/mL. HSP90 (2.1 mg/mL in Dulbecco's PBS containing 2.7 mM potassium
chloride, 1.5 mM potassium phoshate, 137 mM sodium chloride, 8.1 mM sodium phosphate, and
10% glycerol) was obtained from Stressgen. TK1 (0.91 mg/mL in PBS pH 7.4 containing 10%
glycerol) was from GenScript (Piscataway, NJ, USA). Alexa Fluor 488 TFP ester and fluorescein
isothiocyanate (FITC) were obtained from Invitrogen (Carlsbad, CA, USA), while dimethyl
sulfoxide (DMSO) and hydroxypropyl cellulose (HPC, average MW 100 kDa) were from SigmaAldrich. High voltage power supplies were from Stanford Research Systems (Sunnyvale, CA,
USA).
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2.3 METHODS
2.3.1 Hot embossing and bonding
A laser cutter was used to section the PMMA sheets into 54 mm × 38 mm pieces and to form
2.5-mm-diameter holes in the 3-mm-thick PMMA to make the buffer reservoirs. The silicon
template was rinsed with acetone and IPA, and then blow dried with compressed air or nitrogen.
These solvents remove oil and organic residues from surfaces. Since solvents like acetone leave
residues on surfaces, a two-solvent method is used. The silicon template was placed, with the
patterned side facing upwards, on a glass microscope slide. A 1.5-mm-thick piece of PMMA was
set on the template, with another glass slide atop the PMMA (Fig. 2.2A). The glass slides were
sandwiched with copper plates and the assembly held together with C-clamps. The clamps were
not over tightened as this could break the glass slides or template, causing the hot embossing step
to fail. The assembly was placed in the convection oven at 140 °C for 30 min and the elevated
features on the template were transferred onto the PMMA substrate (Fig. 2.2B). The assembly
was removed from the oven and allowed to cool for a few minutes before removing the clamps
and copper plates. The template was then placed against a cooler surface so the imprinted
PMMA pulled away from the template (Fig. 2.2C). Removing the embossed PMMA when the
assembly is totally cooled is not usually a problem. However, detachment after partial cooling
prevents melted PMMA from sticking to the sides of the patterns on the silicon template, which
can affect subsequent patterning.
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Figure 2.2. Schematic overview of the hot embossing procedure. a) Polymer substrate placed on
the silicon template. b) Application of temperature and pressure to transfer pattern from the
template to the substrate. c) Separation of imprinted substrate from the template.
Both the patterned PMMA and the 3-mm-thick cover plate were cleaned with canned
compressed gas for dust removal, and the cover plate was placed on the imprinted PMMA. This
ensured that no particles were trapped in between these plates during bonding, where they could
block the channels. Compressed air can also be used, but canned dust removal with compressed
gas was found to be more effective. The two PMMA pieces were sandwiched with glass slides
and copper plates and then held together with C-clamps as in the imprinting process (Fig. 2.3A).
The C-clamps were the same type and size so uniform pressure was applied to the substrates,
since uneven pressure can cause one side of the device to be over-bonded with the other side
being under-bonded. The assembly was placed in the convection oven at 110 °C for ~25 min to
bond the two pieces together (Fig. 2.3B). Bonding time depended on the number of devices
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being bonded simultaneously. More than two assemblies placed in the oven at the same time
required longer than 25 min. The assembly was removed from the oven and allowed to cool
completely before taking off the C-clamps. The device was then checked to ensure complete
bonding. Schematics of completed device layouts are shown in Figures 2.3C-D.

Figure 2.3. Schematic overview of thermal bonding procedure and completed devices. a)
Imprinted polymer and cover plate placed between glass slides and copper plates, and held
together by C-clamps. b) Thermal bonding of the two pieces. c) Simple two-reservoir device. d)
Multichannel device for automated experiments.
2.3.2 Preparation of porous monolithic columns
To prepare the porous monolithic column 400 mg 1-dodecanol, 300 mg cyclohexanol, 200 mg
GMA, 100 mg EGDMA and 20 mg DMPA were mixed in a glass vial, vortexed briefly and
sonicated until the DMPA was completely dissolved. GMA is the monomer, EGDMA serves as
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the crosslinker, and DMPA functions as the photoinitiator. Half (500 mg) of this solution was
transferred into a clean glass vial and 200 mg of Tween 20 was added to it. The solution was
sonicated for 5 min and immediately purged with N2 for 5 min. The vial containing the remaining
solution was capped and kept in the dark at room temperature to avoid polymerization. This
solution was used within 10 h. It was necessary to repeat the N2 purging before filling the
channel with any stored solution. A small amount of the purged solution was immediately
transferred into reservoir 1 (Fig. 2.3C), and allowed to fill the channel by capillary flow. A fill
time of 2-3 min was allowed to ensure that the channel was completely filled and that the
solution had stopped flowing. The channel can also be viewed under a microscope to ensure that
it is completely filled and that the solution has stopped flowing. Polymerization may be
incomplete or absent if the solution is still flowing during UV exposure. Excess solution was
then removed from the reservoir. This step was important to minimize polymerization in the
reservoir, which resulted in a blocked channel. A schematic procedure for in situ preparation of
the porous monolith is shown in Figure 2.4. A photomask or black tape was used to cover the
regions around the affinity column to make a window for UV exposure (Fig. 2.4B). When black
tape was used the backside of the device, except for the window for exposure, was also covered.
The device was exposed to UV light for 12-14 min at room temperature using the SunRay lamp.
Using a glass mask reduced spurious polymerization but also increased the polymerization time.
With black tape, 12 min was sufficient to polymerize the monolith, but with a photomask 14 min
was needed. Placing a white object under the device to reflect the UV light was also helpful in
obtaining complete polymerization. The tape or photomask was removed and vacuum
immediately applied to remove unpolymerized solution. Then, IPA was flowed through the
channel until the monolithic column became white in color. Immediate removal of
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unpolymerized solution was essential to prevent further polymerization and potential channel
blockage. The channel was flushed with deionized water until the IPA was completely removed,
and then filled with water. If IPA was not completely removed an alcohol-water interface was
formed which could be observed under a microscope. Vacuum was then applied to remove the
water from the device. The monolith appeared black under optical microscope viewing when the
water was removed (Fig. 2.4C). The monolith can be stored dry at room temperature until it is
ready to be functionalized. An electron micrograph of a monolith can be seen in Figure 2.5.

Figure 2.4. Schematic procedure for preparation of a monolith. a) Device filled with prepolymer
mixture. b) Exposure of device to UV radiation through a photomask. c) Monolith formed in the
microchannel.
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Figure 2.5. Electron micrograph of a porous monolithic column formed in a microfluidic
channel. The monolithic structure consists of small globular nodules that offer high surface area,
with an average through pore size of ~2 µm.
2.3.3 Attaching antibodies to the columns
An antibody solution was diluted to 0.5 mg/mL in 50 mM borate buffer (pH 8.6), pipetted into
reservoir 1 (Fig. 2.3C), and allowed to fill the column by capillary action. Tris buffer was
avoided at this stage, because it contains amine groups that react with the epoxy groups on the
monolith. Borate buffer was placed in all other reservoirs to maintain liquid in the channels
during the reaction. The entire chip was sealed with clear adhesive tape and left to react at 37 °C
for 24 h in the dark. When the reaction was completed, the device was flushed with 100 mM Tris
buffer (pH 8.3) for 30 min to deactivate any remaining epoxy groups on the column. The entire
chip was then rinsed with carbonate buffer (pH 9.3) before use.
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2.3.4 Fluorescence labeling of proteins
Proteins were diluted to 1 mg/mL with carbonate buffer, pH 9.3. All but one of the proteins listed
in Section 2.2.3 label efficiently at pH ~9.3; TK1, with a pI of 8.75, did not. The average number
of dye molecules coupled to each TK1 was 0.5 at pH 9.3, 1 at pH 9.8, and ~2 at pH 10.6. This
indicates that TK1 may not be reactive enough at pH 9.3 for efficient labeling. Higher pHs favor
deprotonation of amine groups, resulting in a greater likelihood of reaction between aminereactive dyes and the protein. For FITC labeling, 2 mg of FITC was dissolved in 100 μL of
anhydrous DMSO. Part of this solution (10 μL) was added to 250 μL of protein sample and
incubated in the dark for 3 h at room temperature and then overnight at 4 oC. Any unused label
was discarded as degradation occurred rapidly once the fluorophore was dissolved in solvent.
Unconjugated dye was separated from the protein samples by diafiltration, using an Amicon
Ultra-0.5 centrifugal filter (30 kDa MWCO) and 10 mM PBS, pH 7.4. This step was not
necessary when affinity purification was done on-chip. For labeling with Alexa Fluor 488 TFP
ester, the fluorescent tag was dissolved in DMSO to a concentration of 10 mg/mL. The Alexa
Fluor 488 TFP ester solution (5 μL) and protein sample (200 μL) were mixed and incubated in
the dark for 1 h at room temperature. Sodium azide was added to the labeled proteins to a final
concentration of 2 mM. The fluorescently labeled samples were stored in the dark at 4 oC until
used. For long-term storage, the sample was divided into small portions before freezing. Then,
one portion was removed and used when needed. This avoided repeated freezing and thawing
which could break down the sample.
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2.3.5 Electrophoresis without affinity extraction
Separation buffer was prepared by adding HPC to 10 mM carbonate to a final concentration of
~0.5% to suppress electroosmotic flow and prevent adsorption of proteins to the channel walls.
This buffer was loaded into the device and all reservoirs except reservoir 1 (Fig. 2.3D). Platinum
electrodes were placed in reservoirs 1, 2, 3 and 6 (Fig. 2.3D) and connected to the high voltage
power supplies. Electrophoresis was performed using “pinched injection”.15,

16

For pinched

injection, reservoirs 1, 3, and 6 were grounded while +600 V was applied to reservoir 2. For
separation, reservoir 3 was grounded, +600 V was applied to reservoirs 1 and 2, and +1600 V
was applied to reservoir 6. Fluorescence was detected in the separation channel near reservoir 6
(Fig. 2.3D). An inverted microscope coupled with LIF equipment was used (see Figure 1.6).
Briefly, a 488 nm laser was focused within the separation channel using a 20× 0.45 NA
objective. Fluorescence was collected via the same objective, filtered spectrally and spatially,
and detected at a photomultiplier tube. Detector signal was amplified, filtered and recorded on a
computer. Data points were obtained at 20 Hz.

2.3.6 Affinity extraction
The separation buffer was loaded into the two-reservoir device (Fig. 2.3C). The buffer in the
sample reservoir (reservoir 1) was replaced with protein solution which was loaded on the
affinity column by applying +400 V for 5 min between reservoirs 1 and 2. The sample in
reservoir 1 was then replaced with PBS and the affinity column was rinsed by applying +400 V
for 5 min between reservoirs 1 and 2. For elution, phosphoric acid/dihydrogen phosphate, pH
2.1, replaced PBS in reservoir 1. The low pH was needed to disrupt the protein-antibody
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interaction and elute the protein sample. The retained analyte was then eluted from the column
by application of +400 V between reservoirs 1 and 2.

2.4 RESULTS AND DISCUSSION
Efficient labeling of most of the proteins discussed above occurred at pH ~9 except for TK1.
However, TK1 was better labeled at a higher pH of 10.6. Figure 2.6 shows electropherograms of
TK1 labeled at pH 10.6 before (Fig. 2.6A) and after (Fig. 2.6B) removal of the unreacted label.
µCE of Alexa Fluor 488-labeled TK1 showed complete separation of the unreacted dye and the
labeled protein.

Figure 2.6. Electropherograms of 500 ng/mL Alexa Fluor 488-labeled TK1 (A) before and (B)
after removal of dye.
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Proteins were fluorescently labeled and extracted on an affinity monolith. I have studied the use
of porous monoliths for the extraction of HSP90 in a device like the one in Figure 2.3C. The
monolith was prepared and functionalized with anti-HSP90 as described above. To test the
specificity of the anti-HSP90 column, the fluorescent dye Alexa Fluor 488 TFP ester was loaded
on a functionalized and unfunctionalized column by the application of voltage (see Figure 2.7).
Elution was carried out with phosphoric acid/dihydrogen phosphate buffer, pH 2.1, and the
fluorescence intensity was measured with a PMT. When Alexa Fluor 488 was flowed through an
unfunctionalized column, a significant amount was extracted and subsequently eluted (Fig.
2.7A), since there is increased non-specific sorption of dye when antibody is not bound to the
affinity column. When the column was functionalized with anti-HSP90 very little Alexa Fluor
488 was eluted from the column as evidenced by the small eluted peak (Fig. 2.7B). The limited
amount of dye eluted could be the result of its reaction with the protein on the column which
could cause it to remain attached to the column.

Figure 2.8 shows the elution of Alexa Fluor 488-labeled HSP90 from a functionalized column.
The labeled HSP90 attached to anti-HSP90 by the specific antibody-antigen interaction as it
flowed through the column. The elution intensity can give an indication of the amount of protein
that was attached to the column. The elution profile in this case showed that a significant amount
of HSP90 was extracted, even though the fluorescent intensity is partially quenched by the low
pH of the elution buffer. These results demonstrate that prior removal of unreacted label is not
necessary with the use of these affinity columns. Functionalized columns could be used to
extract other proteins in a similar manner, and extraction of multiple proteins could be achieved
by immobilizing their respective antibodies on a single column.
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Figure 2.7. Elution profiles of 0.5 µg/mL Alexa Fluor 488 TFP ester from an affinity column
that was a) unfunctionalized, and b) functionalized with anti-HSP90.

Figure 2.8. Elution profile of 1 µg/mL HSP90 from an affinity column that was functionalized
with anti-HSP90.
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3. ION-PERMEABLE MEMBRANE FOR ON-CHIP PRECONCENTRATION AND
SEPARATION OF CANCER MARKER PROTEINS *

3.1 INTRODUCTION
Cancer, a malignant and invasive growth of cells in the body, is the second most common cause
of death in the US.1 Survival rates in some cancer types have improved over the years, due in
part to detection at an early stage when the cancer can be easily treated.2-4 The development of
cost-effective techniques that are sensitive and specific enough to diagnose cancer at an earlier
stage than is currently possible will further improve cancer survivability. Cancer biomarkers
have been shown to enable early detection, and facilitate the prognosis and monitoring of the
response to cancer therapy.2 However, of the numerous proteins proposed as cancer biomarkers
only nine have been approved by the FDA,5 one of which is α-fetoprotein (AFP), a diagnostic
marker for hepatocellular carcinoma. AFP is a 67 kDa glycoprotein which has high levels in fetal
sera.6 Its concentration decreases to trace levels soon after birth; therefore, raised AFP levels in
adult serum usually indicate a disease state. Another biomarker of interest is heat shock protein
90 (HSP90), a 90 kDa molecular chaperone that oversees the proper folding of newly formed
proteins. Many HSP90 clients are proteins whose mutation or overproduction promotes cancer,
making HSP90 inhibition a target in cancer therapy.7, 8 Even though HSP90 is presently not FDA
approved, its elevated levels in many human cancer types indicate potential utility for diagnosis
and the monitoring of response to treatment.9 Enhanced detection of these and other biomarkers
is thus important in early detection of cancer and follow-up of cancer therapy.

* This chapter is reproduced with permission from Electrophoresis, Nge, P. N.; Yang, W.; Pagaduan, J. V.;
Woolley, A.T., Electrophoresis 2011, 32, 1133-1140. Copyright 2011 Wiley-VCH Verlag GmbH & Co.
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A diagnostic technique that is applicable to point-of-care (POC) settings needs to be fast,
sensitive and quantitative.10 The method commonly used for protein detection is ELISA, which
is effective for a large number of samples and thus best suited for clinical settings rather than
POC analysis.10 Microfluidic devices are attractive for POC analysis because they offer the
benefits of portability, minimal solvent and reagent consumption, and speed.11 Microchip
capillary electrophoresis (µ-CE) in particular has been successfully applied to the analysis of
different types of molecules, including cancer biomarkers.12-14 An appealing aspect of
miniaturization is integration: various components can easily be combined in these devices to
perform multiple tasks including analyte extraction, control of fluidic movement and sample
preconcentration. While microfluidics improves on the slower analysis times offered by
ELISA,10 the small volumes and pathlengths can lead to reduced sensitivity. Therefore,
microfluidic assays could benefit considerably from integrated methods to improve the limits of
detection.15

Several stacking procedures have been successfully used for sample preconcentration in a
microfluidic format including field amplified sample stacking,16 field amplified sample
injection,17 isotachophoresis (ITP),18,

19

electric field gradient focusing,20 temperature gradient

focusing (TGF),21 isoelectric focusing (IEF),22 electrokinetic supercharging,23 and sweeping.24
Sometimes two of these techniques can be combined for improved results. Munson, et al.21
combined a form of sample stacking, field amplified continuous sample injection, with TGF. The
combination of electrokinetic injection with transient ITP has also been coupled with gel
electrophoresis.18 While methods like ITP and IEF may be compatible with µ-CE, they often
require two or three different buffers, which complicate execution in a microchip format.
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Moreover, the required coupling of many of these techniques with microchip gel electrophoresis
renders the overall separation process more challenging. A technique known as electrophoretic
exclusion has recently been used to achieve both selectivity and enrichment of proteins by
manipulating voltage in combination with hydrodynamic flow.25 The simplicity of this method
promises potential for future application in a microchip format.

Other preconcentration methods for microfluidic systems involve affinity techniques like solid
phase extraction (SPE),26 and exclusion methods based on nanogaps27, 28 or nanoporous filters.15,
29-35

In affinity methods the analyte is generally made to adsorb to a column, and a different

solution is used to elute the retained components. Affinity techniques are effective but are
complicated by the need for different buffers to be used in pretreatment and analysis. Enrichment
based on exclusion generally offers a simpler analysis setup, but a more complex device
fabrication process. Nanogaps can be formed via photolithography29 or by applying a high
voltage to a PDMS-glass device to cause dielectric breakdown.27,

28

In nanogap devices,

preconcentration without subsequent separation has been done, but the process was lengthy (3060 min).28 In contrast, membrane-based preconcentration methods are generally faster than with
nanogaps, and the fabrication methods have a range of complexity. Some materials used to
fabricate these membranes are polycarbonate (PC),33 track-etched PC,32, 36 titania,29 nafion,37 and
silica gel.31 These membrane materials were anionic to concentrate analytes based on charge
exclusion. For several device arrangements preconcentration only, without protein separation,
was done.29, 32, 33, 37 Long et al.36 used a track-etched PC membrane to concentrate Rhodamine
123 and FITC-labeled ephedrine samples 1000-fold by SPE-µCE; however, the technique
required careful timing of online injection after the SPE process. Foote et al.31 used a porous
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silica membrane in a glass microchip to obtain signal enhancement of ~600-fold by on-chip
preconcentration followed by sodium dodecyl sulfate (SDS) – microchip gel electrophoresis
separation. However, the use of glass devices and the coupling of a preconcentration membrane
with gel-based separation require a more complicated fabrication process.

Hydrogel membranes involving acrylic monomers offer a special type of preconcentration
system and can be either neutral or charged.15, 30, 34, 35 The pore size of these membranes and their
mechanical properties can be controlled by varying the ratio of cross-linking agent to acrylamide.
Hatch et al.15 integrated two acrylic polymer hydrogel structures in a glass device: one for sizebased preconcentration (up to 1000-fold) and the other to separate the preconcentrated sample by
SDS-gel electrophoresis. However, the fabrication of two different gels in a microdevice was
somewhat complicated, and the proteins analyzed had to be denatured to achieve separation.
Addition of an ionic comonomer, such as 2-acrylamido-2-methylpropanesulfonic acid (AMPS),
to acrylamide imparts a negative charge and enables the membrane to be ion-selective.38 This
type of polymer membrane has been used for the preconcentration of model proteins,30 but in
that work preconcentration was not coupled to separation. In addition, Chun et al.35 fabricated a
glass microchip with a hydrogel made entirely of crosslinked AMPS; however, protein
separation was not performed in conjunction with preconcentration. Yamamoto et al.34 made a
polymer membrane combining acrylamide and AMPS, and used it to couple 105-fold
preconcentration with µ-CE of separate samples of oligosaccharides, α1-acid glycoprotein, and
glycopeptides, but not to analyze a mixture of proteins. Their monomer and crosslinker
concentrations were high at 26% T and 20% C; moreover, the standard device layout did not
make it easy to remove monomer solution after membrane polymerization. In summary,
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hydrogel-based microchip preconcentration systems show promise in their ability to be finetuned easily, but simplifying fabrication procedures and application to the separation of proteins
still needs further effort.

In this chapter, a polymer membrane was fabricated in situ and used for on-line preconcentration
prior to separation of cancer marker proteins. The membrane consisted of acrylamide, N,N’methylene-bisacrylamide and AMPS, and was photopolymerized in the microdevice near the
injection intersection region. Negatively charged proteins were excluded from the porous
membrane, enabling their enrichment. Initial characterization of the device with bovine serum
albumin (BSA) led to a 40-fold enrichment in the µ-CE peak with 4 min of preconcentration
time. Fine-tuning of the buffer pH provided baseline resolution of model cancer marker proteins,
and careful control of preconcentration time kept peak broadening to a minimum. More than 10fold enhancement of µ-CE signal in a protein mixture was achieved with just 1 min of
preconcentration, and the entire analysis was completed in <5 min. Our approach provides a
simple and fast route to the analysis of low-concentration samples.

3.2 EXPERIMENTAL SECTION
3.2.1 Reagents and materials
The monomers acrylamide and AMPS, as well as the cross-linking agent N,N’-methylenebisacrylamide were purchased from Sigma-Aldrich (St. Louis, MO). Riboflavin was obtained
from Eastman (Rochester, NY), tetramethylethylenediamine (TEMED) was from Invitrogen
(Carlsbad, CA), and ammonium persulfate (APS) was obtained from EMD Chemicals
(Gibbstown, NJ). Bovine serum albumin (BSA) was purchased from New England Biolabs
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(Ipswich, MA), heat shock protein 90 (HSP90) was from Sigma-Aldrich and alpha-fetoprotein
(AFP) was from Lee Biosolutions (St Louis, MO). The proteins were labeled with fluorescein
isothiocyanate (FITC) or Alexa Fluor 488 TFP ester purchased from Invitrogen. Dimethyl
sulfoxide (DMSO) was purchased from Sigma-Aldrich. Hydroxypropyl cellulose (HPC, average
MW 100 000) was from Aldrich (Milwaukee, WI). PBS buffer (10 X, pH 7.4), anhydrous
sodium carbonate, sodium bicarbonate, and sodium azide were purchased from EMD Chemicals.
Amicon Ultra-0.5 centrifugal filter devices were obtained from Millipore (Billerica, MA).

3.2.2 Device fabrication
The microchips were made from poly(methyl methacrylate), PMMA, using a combination of
photolithographic techniques, hot embossing and thermal bonding as previously described in
Section 2.3.1.39 The microchip design, shown in Figure 3.1A, is similar to an offset-T device,
except for the addition of two reservoirs (4 and 6) and the channels leading to them. The channel
connected to reservoir 4 helped to empty monomer solution from the channel leading to reservoir
2 after polymerization of the membrane. The channel leading to reservoir 6 provided for crossinjection, as an alternative to offset-T injection. The channels were ~15 µm deep and ~50 µm
wide.
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Figure 3.1. Photograph of a microfluidic device and zoom view of a preconcentration
membrane. (A) Photograph of the microfluidic device used for sample preconcentration.
Reservoir labels are 1, sample; 2, sample waste; and 3-6, buffer. The channel connected to
reservoir 4 helped to empty the monomer solution from the channel leading to reservoir 2 after
polymerization of the gel. The channel leading to reservoir 6 provides cross-T injection while the
channel connected to reservoir 1 provides offset-T injection. (B) Photomicrograph of
microchannel intersection region showing position of the polymerized membrane, indicated by
the black arrow.
Before gel polymerization the microchannels were conditioned sequentially with 0.1 M HCl and
0.1 M NaOH, rinsed with deionized water and dried with vacuum. This made the channel surface
more hydrophilic and improved adhesion of the membrane to the channel walls.40, 41 The pore
size of the membrane depends on the total amount of acrylamide present (%T), and the amount
of cross-linker (%C), where T is percentage of acrylamide, bisacrylamide and AMPS, expressed
in grams per 100 mL of mixture, and C is the percentage of bisacrylamide in the total monomer
content. To fabricate the membrane, an 8% T and 5% C monomer solution was prepared. The
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mass percent of AMPS in the total mixture was 0.5%. The solution was filtered with a 0.2 μm
syringe filter and degassed. To initiate polymerization, riboflavin and APS were added to a final
mass percent of 0.004% and 0.008%, respectively, followed by addition of 1.5 μL of TEMED
per mL of monomer solution. A 10 μL aliquot of the monomer solution was immediately placed
in reservoir 3 and left for a few seconds to fill the microchip by capillary action, after which the
remaining solution in reservoir 3 was removed to prevent hydrodynamic flow during
photopolymerization. A 488 nm laser beam (1 mW) was focused on the membrane location for
~45 s to produce a polymer membrane with diameter of ~60 μm (Figure 3.1B). The
unpolymerized monomer solution was then removed from the chip using vacuum, and the
channels were rinsed with deionized water.

3.2.3 Fluorescent labeling
The protein solutions were prepared in carbonate buffer, pH 9.2, at a concentration of 2 mg/mL.
FITC solution was prepared by dissolving 2 mg of FITC in 100 μL of anhydrous DMSO. This
FITC solution (10 μL) was added to 250 μL of protein sample and incubated in the dark, first for
3 h at room temperature and then overnight at 4 ºC. For labeling with Alexa Fluor 488 TFP ester,
the dye was dissolved in DMSO to a concentration of 10 mg/mL. Dye solution (5 μL) was added
to 250 μL of sample and incubated in the dark for 1 h at room temperature. The unconjugated
dye in each case was separated from the protein samples by diafiltration, using an Amicon Ultra0.5 centrifugal filter device (30 kDa MWCO) and 10 mM PBS, pH 7.4. The labeled protein was
collected, and sodium azide was added to a final concentration of 2 mM. The fluorescently
labeled samples were stored in the dark at 4 ºC until used.
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3.2.4 Electrophoresis experiments
The separation buffer for single-component samples was 10 mM carbonate (pH 9.2) containing
0.1% HPC, while that for the protein mixture was 10 mM phosphate (pH 7.0) containing 0.05%
HPC. Buffer solution was filled in the channels and all reservoirs, except reservoir 1 which was
filled with the sample solution (20 µL). Platinum electrodes were placed in reservoirs 1, 2, 3 and
5. The electrodes were connected to high voltage power supplies (Stanford Research Systems,
Sunnyvale, CA) via a custom-built switch. Electrophoresis involved a standard “pinched
injection” with an offset-T layout.42, 43 For injection, reservoirs 1, 3, and 5 were grounded while
600 V were applied to reservoir 2. For separation, reservoir 3 was grounded, 600 V were applied
to reservoirs 1 and 2, and 1600 V were applied to reservoir 5.

The laser-induced fluorescence system used to detect the analytes has been described
previously.44 Briefly, sample excitation was done with a 488 nm laser (Ar ion) focused at a spot
in the channel close to reservoir 5 using a 20× 0.45 NA objective. Emitted photons were detected
(after spectral and spatial filtering) with a photomultiplier tube, then amplified and filtered, and
finally recorded on a computer. The data sampling rate was 20 Hz.

3.2.5 Data analysis
Calculation of concentrations was based on peak areas, obtained by subtracting the background
individual signal values from a given peak and then summing the results. For comparison, the
peak height was obtained by subtracting the baseline from the peak maximum. For
preconcentration of HSP90 and AFP, control data were obtained from similar chips without a
preconcentration membrane. The peak areas or heights obtained after preconcentration were then
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divided by the corresponding areas or heights before preconcentration to determine the amount
of preconcentration that occurred.

3.3 RESULTS AND DISCUSSION
The devices used for these experiments were designed to provide a good yield during
polymerization of the preconcentration membrane. When a simple offset T design was used, it
was difficult to empty the channel arm of the microchip leading to reservoir 2 (Figure 3.1A) after
polymerization of the gel. Therefore, a channel connected to reservoir 4 was added to facilitate
the flushing process after polymerization. Our device layout can also be used for either crossinjection (sample in reservoir 6) or offset-T injection (sample in reservoir 1). In the experiments
reported here, offset-T injection was used to increase sample plug volume.

The membrane was photopolymerized in the injection channel just beyond the intersection
region (Figure 3.1B). The properties of acrylamide gels were found to depend not only on the
monomer composition but also on polymerization conditions. When riboflavin only was used as
the initiator, polymerization was much slower (5-10 min), and the resulting membrane was more
porous and less stable. Addition of APS decreased polymerization time and made the process
more reproducible. In addition, when these two initiators were combined the total amount of
initiator was lower, decreasing undesirable side effects caused by excess initiator
concentration.45 The diameter of our membrane was ~60 µm. Larger membranes increased the
electrical resistance, leading to a higher voltage drop across the membrane, which negatively
affected separation efficiency.15 The apparent pore radius for a 10.5% T, 5% C gel was reported
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to be 21 nm,46 so our 8% T, 5% C gel is estimated to have a pore radius somewhat larger than
that.

BSA was used initially to test the effectiveness of the preconcentration membrane. The buffer
was 10 mM carbonate, pH 9.2 with 0.1% HPC added to suppress electroosmotic flow (EOF).
Previous experiments had shown that 0.5% HPC was effective in suppressing EOF to yield
reproducible results;39 however, 0.5% HPC was found to block the membrane, resulting in poor
separation. Thus, lower HPC concentrations were used (0.05-0.1%) which did not block the
membrane but still provided adequate separation efficiency.

Electropherograms of increasing concentrations of BSA (Figure 3.2A) show corresponding
increases in peak area. Figure 3.2B shows µ-CE of 5 nM BSA without preconcentration, along
with other electropherograms after on-chip preconcentration times of 30 s to 4 min.
Preconcentration times of 30 s to 1 min produce ~10-fold enhancement of signal without
compromising the peak shape. A larger, 20-fold enhancement was produced with 2 min
preconcentration, but peak tailing was beginning to be evident. By 4 min of preconcentration a
significant degree of peak tailing occurred with the ~40-fold enrichment. Thus, enrichment
factors of at least 10 can be obtained quickly and without distortion of peak shape; even higher
factors (~40) can be achieved if some peak shape distortion can be tolerated.

72

Figure 3.2. Dependence of peak width on sample concentration and preconcentration effects on
peak width. (A) Dependence of peak shape on injected BSA concentration during µ-CE. BSA
concentrations are: 1 nM, black; 5 nM, blue; 20 nM, red; 50 nM, green. (B) Effect of
preconcentration time on BSA signal during µ-CE; all traces are for 5 nM initial BSA
concentration. The preconcentration times for the curves are: 0 min (no preconcentration), black;
0.5 min, blue; 1 min, red; 2 min, green; 4 min, violet. All electropherograms are offset vertically
for clarity.
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Peak tailing at longer preconcentration times could be caused by concentration polarization (CP),
which occurs when current traverses an ion-selective membrane.47 Increased cation and anion
concentrations on alternate sides of the membrane make a concentration gradient that increases
the electrical resistance across the membrane, resulting in a local voltage drop.48 This voltage
drop reduces the effectiveness of the potentials applied to reservoirs 1 and 2 during separation to
prevent sample leakage and pull remaining analyte out from the intersection,49 leading to peak
tailing. Since this CP-induced voltage drop increases as a function of preconcentration time,15, 48
most of our experiments were carried out with a preconcentration time of ~1 min to limit these
tailing issues.

Quantitation of the BSA samples was done on the basis of peak area, which increased linearly as
a function of concentration, as seen in Figure 3.3A. Figure 3.3B similarly shows a linear increase
in BSA peak area with preconcentration time for the range of 0.5 to 4 min. A 5 min
preconcentration time (result not shown) resulted in a peak with severe tailing and a height that
was lower than that in the 4 min result. At this point the negative factors associated with a long
preconcentration time became apparent. This tailing puts an upper limit of ~4 min on the
preconcentration time, to allow for adequate separation performance in µ-CE.
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Figure 3.3. Dependence of µ-CE peak area on BSA concentration and preconcentration time.
(A) Plot of peak area as a function of BSA concentration. The slope is 0.71 ±0.02, and the
intercept is -0.21 ± 0.16, with R2 = 0.9972. (B) Plot of peak area as a function of
preconcentration time. The slope is 15.10 ±0.60, and the intercept is -0.7 ± 1.5, with R2 = 0.9959.

The preconcentration and separation conditions optimized for BSA were next applied to AFP
and HSP90. Preconcentration of 5 nM HSP90 having a small amount of FITC (Figure 3.4A) was
done for 4 min, resulting in ~80-fold enrichment of the HSP90 peak in the electropherogram.
The enriched peak was symmetrical, but its migration time was somewhat slower than in the
separation without preconcentration. The slower migration time was likely due to some CP
occurring during this longer preconcentration time, as noted above. The FITC peak in the
separation without enrichment was almost undetectable; however, the peak became readily
observable after preconcentration, with ~20 fold enhancement. Even though the pore size of the
membrane was large enough to allow the passage of FITC, electrostatic repulsion between FITC
and the AMPS in the membrane allowed some preconcentration. The preconcentration of 10 nM
AFP for 1 min in Figure 3.4B yielded a symmetrical peak with an enrichment factor of 16. The
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AFP peak was somewhat broader and migrated slower than the HSP90 peak in the separation
without preconcentration.12
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Figure 3.4. Preconcentration and µ-CE of cancer-related proteins. (A) Preconcentration of 5 nM
HSP90. The peak at ~23 s is FITC. HSP90 (peak at ~42 s) is concentrated ~80-fold with the 4
min preconcentration time. (B) Preconcentration of 10 nM AFP. AFP is concentrated ~15-fold in
1 min. In both (A) and (B) the trace in black represents µ-CE without preconcentration, while the
blue trace denotes preconcentration followed by µ-CE separation.

To determine if the peak width of AFP was influenced by the FITC tags, AFP was also labeled
with Alexa Fluor 488. The µ-CE peak produced by Alexa Fluor 488-labeled AFP was ~2 s
narrower than that of FITC-labeled AFP (Figure 3.5), most likely due to reduced impacts of
multiple site labeling. However, the electrophoretic mobility of Alexa Fluor 488-labeled AFP
was slightly faster than FITC-labeled AFP, so when run with HSP90 there was a higher degree
of peak overlap. In these experiments the chip-to-chip reproducibility in migration time for
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the same sample under the same conditions was ±1s while the reproducibility in peak height
depended on the channel heights. Chips fabricated from the same template had good peak
height reproducibility of ±0.2 units (on a scale of 0-5). The peak height variability for chips
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made from different templates was as much as ±1 unit on this same scale.
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Figure 3.5. Electropherograms of 50 nM AFP labeled with FITC (bottom) and Alexa Fluor 488
TFP ester (top). Traces are offset vertically. AFP labeled with FITC was about ~2 s broader than
that labeled with Alexa Fluor 488. Peak intensity was ~2-fold higher with Alexa Fluor 488labeled AFP than the FITC-tagged protein, and this peak also had a higher electrophoretic
mobility.
I found that the resolution of AFP and HSP90 depended on the pH. Poor resolution was obtained
when electrophoresis was carried out in 10 mM carbonate buffer (pH 10.5) but resolution
improved to near baseline at pH 9.2, with baseline resolution being achieved with a pH of ~7
(Figure 3.6). Liu et al.50 likewise noticed an improvement in protein resolution at lower pH,
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which they believed was caused by an increase in the charge difference between proteins at pH
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Figure 3.6. Effect of pH on resolution of a mixture of HSP90 and AFP. The pHs were from
bottom to top: 7.0, 9.2, 10.0, and 10.5. Resolution is improved at lower pHs.
Preconcentration and separation of mixtures of different concentrations of HSP90 and AFP
(Figure 3.7) show well-resolved peaks with 1 min preconcentration time. The enrichment factors
for HSP90 and AFP in the 10 nM mixture were 10- and 16-fold, respectively, while those for the
20 nM mixture were 7- and 13-fold, respectively. Thus, a slightly higher enrichment factor was
achieved with lower sample concentrations. AFP also showed a higher level of preconcentration
compared to HSP90, which could be attributed to factors such as size, charge, or mobility. The
diagnostic threshold has been reported to be 20 ng/mL (0.3 nM) for AFP12 and ~20 ng/mL (0.2
nM) for HSP90.51,
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Detection limits achieved with this preconcentration technique are ~42

ng/mL for AFP and ~6 ng/mL for HSP90. Though the limit of detection for AFP is above the
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diagnostic threshold, it can be easily improved by a slight increase in preconcentration time. An
additional enrichment factor of 10-fold or more could be achieved by optimizing the pore size
and charge of the membrane such that longer preconcentration times could be used without
compromising separation efficiency. Importantly, these results demonstrate a rapid and simple
procedure by which multiple cancer biomarkers can be concentrated ~10-fold or more with a
straightforward, 1 min process prior to µ-CE analysis.
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Figure 3.7. Preconcentration and µ-CE of cancer-related proteins. Mixture of HSP90 and AFP;
(A) 10 nM and (B) 20 nM. Preconcentration time was 1 min. The black traces represent µ-CE
without preconcentration, while the blue traces denote preconcentration followed by separation.
Enrichment factors are given in the text.
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4. MICROFLUIDIC CHIPS WITH REVERSED-PHASE MONOLITHS FOR SOLID
PHASE EXTRACTION AND ON-CHIP LABELING *

4.1 INTRODUCTION
The integration of multiple functions in a single device can result in faster, cheaper and improved
analysis compared to traditional laboratory methods.1 Many such processes have been integrated
in microfluidic devices, including extraction/purification,2-6 labeling,7,
microdialysis,11,

12

and detection.13,

14

8

preconcentration,9,

10

One of the greatest difficulties in achieving completely

miniaturized and integrated analysis has been the step of sample preparation,15 although
important progress is being made in selected areas as noted below. Importantly, solid phase
extraction (SPE) has been used in integrated sample processing, including extraction,
purification and preconcentration.2, 5, 6

SPE is a common sample preparation method wherein analytes are retained on a solid support
and are subsequently eluted in a concentrated form.16 The most common SPE modes in
microfluidics are affinity4, 17, 18 and reversed-phase.6, 19, 20 Affinity SPE in microchips has been
used to extract and quantify four cancer biomarkers in blood,4 to preconcentrate and purify PCR
products,17 and to extract thiazole orange-conjugated adenosine monophosphate.18 Reversedphase columns are useful in the extraction of non-polar to moderately polar compounds. Silicabased materials are common reversed-phase SPE supports, having been used for the extraction of
parabens and fluorescent dyes,6 the preconcentration of peptides and cytochrome c,19 and the
concentration and separation of Rhodamine 123 and fluorescein isothiocyanate (FITC)-labeled

* This chapter is reproduced with permission from Journal of Chromatography A, Nge, P. N.; Pagaduan, J. V.; Yu,
M; Woolley, A. T., J. Chromatogr. A 2012, 1261, 129-135. Copyright 2012, Elsevier.
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ephedrine.20 Monolithic columns are seeing increased usage because they can be easily prepared
on-chip without the need for retaining structures like frits,5, 21 and the porosity and surface area
can be tuned by varying the monomer/porogen composition.22 Neutral methacrylates are
generally hydrophobic enough for reversed-phase SPE.23, 24 Cyclic olefin copolymer (COC) is a
preferred polymer material for SPE microchips because of its stability in organic solvents such as
acetonitrile that are used for elution.24, 25 Though photografting is generally used to modify the
microchannel for enhanced monolith/wall adhesion,24 it has also been shown that monoliths
fabricated in COC devices can be stable without surface pretreatment.26

The integration of SPE with capillary electrophoresis or microchip electrophoresis (µCE) offers
the advantages of improved sensitivity and sample cleanup, along with shorter analysis times,
reduced sample loss and increased automation.20, 27 Typically, when SPE is coupled to µCE, an
interface is used to control the transfer of analytes from the SPE column to the separation
channel. In the analysis of dopamine by SPE-µCE, polydimethylsiloxane (PDMS) microvalves
were used to segregate the processes of extraction, rinsing, sample elution and separation.23 In a
different setup, a nanoporous membrane sandwiched between two PDMS layers was used as an
electrokinetic valve to separate the processes of SPE and electrophoretic separation.20 In these
PDMS SPE-µCE systems, separation of small molecules was done, which is less complicated
since they typically do not bind as much as proteins to the device walls.28

Many samples do not fluoresce naturally and have to be derivatized to take advantage of the
superior sensitivity of laser-induced fluorescence detection. Labeling is often performed off-chip,
but on-chip labeling has been achieved both in pre-column7, 8, 29 and post-column30-32 formats.

83

Conventional dyes with high quantum yield, such as Alexa Fluor and fluorescein, are often used
to label analytes. Additionally, fluorogenic reagents,7,

8, 33

which are weakly fluorescent until

they react with a primary amine, have been used for on-chip derivatization because they produce
lower background fluorescence, their reaction kinetics are fast, and they do not change the
electrical charge of the sample.34 The fluorogenic reagents, CE dye 503,7 ThioGlo-1,8 and
naphthalene-2,3-dicarboxaldehyde,35 have been used for on-chip derivatization. While
acceptable results were obtained from these integrated systems, lower limits of detection,
avoiding on-line mixing of high concentrations of fluorescent dyes, and addressing system peaks
and background fluorescence are all areas where improvement is desirable.

In this chapter I demonstrate a novel approach combining SPE with on-chip labeling and
purification to improve over previous methods. I show that samples retained on a solid support
can be concentrated and labeled on-chip prior to elution. Reversed-phase butyl methacrylate
(BMA) porous polymer monoliths were formed in COC microdevices and used to study the
retention of fluorophores, amino acids and proteins. The retained and concentrated samples were
then labeled on-chip with Alexa Fluor 488 TFP ester or Chromeo P503. Subsequent rinsing to
remove unreacted dye and selective elution of labeled sample relative to unconjugated
fluorophore helped to greatly reduce the background fluorescence typically observed in on-chip
labeling. On-chip labeling of heat shock protein 90 (HSP90) resulted in a concentrationdependent area of the eluted peak, demonstrating the ability of this method to quantify on-chip
labeled samples. This chapter thus offers improved capabilities in on-chip labeling for
miniaturized analysis.
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4.2 EXPERIMENTAL
4.2.1 Reagents and materials
Zeonor 1020R (COC) was purchased from Zeon Chemicals (Louisville, KY, USA). Methyl
methacrylate (MMA), BMA, lauryl methacrylate (LMA), 2,2-dimethoxy-2-phenylacetophenone
(DMPA), 1-dodecanol, cyclohexanol, Tween 20, ethylene dimethacrylate (EDMA), and
isopropyl alcohol were obtained from Sigma-Aldrich (St. Louis, MO, USA). Bovine serum
albumin (BSA) was purchased from New England Biolabs (Ipswich, MA, USA) and HSP90 was
from Sigma-Aldrich. The amino acids glycine, aspartic acid, phenylalanine and arginine were
obtained from Sigma-Aldrich. The amino acids were labeled with FITC, while the proteins were
labeled with Alexa Fluor 488 TFP ester. Both fluorophores were from Invitrogen (Carlsbad, CA,
USA). Chromeo P503 was obtained from Active Motif (Carlsbad, CA, USA). Fluorescein
(sodium salt) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich.
Hydroxypropyl cellulose (HPC, 100 kDa average molecular weight) was from Aldrich
(Milwaukee, WI, USA). Sodium dodecyl sulfate (SDS) was obtained from Fisher Scientific
(Pittsburgh, PA, USA). Buffer solutions were made from anhydrous sodium carbonate, sodium
bicarbonate, acetonitrile (ACN), and sodium azide, all from EMD Chemicals (Gibbstown, NJ,
USA). Amicon Ultra-0.5 centrifugal filter devices were obtained from Millipore (Billerica, MA,
USA). All solutions were prepared with deionized water (18.3 M
Ω cm) purified by a Barnstead
EASYpure UV/UF system (Dubuque, IA, USA).

4.2.2 Device fabrication
COC plates were obtained by cutting the sheets into 2" x 1" pieces with a bandsaw. Holes in the
cover plate were then drilled to serve as reservoirs in the bonded devices. The microdevices were

85

fabricated using a combination of photolithographic patterning, etching, hot embossing and
thermal bonding as described in Section 2.3.1.36 Bonding of COC was done at 110 ºC for 20 min.
Two different microchip designs were used for these experiments. A simple, two-reservoir layout
(Fig. 4.1A) was used for initial testing while the design in Figure 4.1B was used for integrated
experiments where no exchange of liquids in reservoirs was required. The channels in both
designs were ~15 µm deep and ~50 µm wide. Before polymerization of a monolith, the channels
were rinsed with isopropyl alcohol.

Figure 4.1. Schematic of microfluidic devices used for on-chip labeling. a) Simple, two reservoir
design used for initial testing. b) Layout used for integrated experiments. The reservoirs are: 1 –
sample, 3 – fluorescent dye, 4 – rinse buffer, 5 – eluent, and 2 and 6 – buffer. The lengths from
reservoirs 1, 2, 4 and 5 to the injection intersection are all 0.5 cm.
4.2.3 Preparation of SPE monoliths
Monoliths were made from a solution consisting of 25% BMA (or MMA or LMA), 15% EDMA,
25% (w/w) dodecanol, 10% cyclohexanol, and 25% Tween 20. 1% DMPA was added to the
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mixture as photoinitiator. The solution was sonicated for 10 min and degassed for 5 min. It was
then filled into the device, and a mask was used to expose only the desired portion of the chip to
UV radiation. Exposure was carried out with the use of a SunRay 600 UV floodlight from
Uvitron International (West Springfield, MA, USA) at 50 mW/cm2 for 10 min. A 2 mm long
monolith was formed in each microdevice in the location indicated in Figure 4.1. After
polymerization, devices were rinsed with isopropyl alcohol followed by buffer (10 mM
carbonate, pH 9.3). The morphology of the monoliths was characterized using a Philips XL30
FEG environmental scanning electron microscope (SEM) from FEI (Hillsboro, OR, USA).

To determine the loading capacity of the monoliths, increasing concentrations of BSA were
loaded on column using a syringe pump (Harvard Apparatus, Holliston, MA, USA) operating at
20 μL/min. First, the column was preconditioned with carbonate buffer containing 30% ACN,
and then each BSA solution was loaded for 10 min (200 μL total volume), followed by a 5 min
rinse with aqueous carbonate buffer. BSA retention was monitored via the backgroundsubtracted fluorescent intensity at the CCD detector.

4.2.4 Off-chip labeling
Amino acids were separately mixed with FITC at a 4:1 molar ratio and incubated at room
temperature for 24 h. This ratio ensures that almost no unreacted dye is left at the end of the
labeling process. BSA and HSP90 were labeled with Alexa Fluor 488 TFP ester as described in
Section 3.2.3.9 The labeled samples were analyzed by µCE as described in Section 3.2.49 to
confirm the lack of free dye, before loading into the monolithic column. A stock solution of
Chromeo P503 was made by dissolving the dye in DMSO to a concentration of 0.8 mg/mL. For
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off-chip labeling of BSA with Chromeo P503, the protein and dye were mixed to final
concentrations of 5 µg/mL and 70 µg/mL, respectively, and incubated for 30 min at room
temperature.

4.2.5 Microdevice operation
Before sample loading, monolithic columns were preconditioned with different solutions to find
the most favorable conditions for sample sorption. The different pretreatments included rinsing
the monolith with aqueous carbonate buffer (10 mM, pH 9.3), with carbonate buffer containing
30% ACN just prior to sample loading, or with carbonate buffer containing 30% ACN followed
by thorough rinsing with aqueous carbonate buffer. I used pH 9.3 for all buffers except the
eluent, because at pH values above 9 the ε-amino groups on proteins are mainly deprotonated,37
facilitating labeling.

After column preconditioning, device operation for the simple design (Fig. 4.1A) was as follows.
For retention and preconcentration studies, labeled sample in carbonate buffer was loaded on the
monolithic column by applying +400 V to reservoir 2 and grounding reservoir 1 for 5 min.
Rinsing was done by replacing the sample in reservoir 1 with carbonate buffer and applying the
same voltages as before for 2 min. For elution, the rinse buffer in reservoir 1 was replaced with
eluent consisting of 85% ACN, 15% carbonate buffer (7.5 mM, pH 9.6), 0.05% HPC, and 0.05%
SDS. Elution was accomplished by grounding reservoir 1 and applying +1000 V to reservoir 2.
On-chip labeling with Alexa Fluor 488 (TFP ester) was done by transferring protein solution into
reservoir 1 and applying the same column loading voltages as above for 10 min. Next, 50 µg/mL
of labeling solution was placed in reservoir 1, which was grounded, and +400 V were applied to
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reservoir 2 for 15 min. This was followed by rinsing and elution as above. For on-chip labeling
with Chromeo P503 the voltage polarity was reversed during loading of the dye and the rinse
because of the positive charge on the label. The polarity was restored to positive for elution.

Experiments with the design in Figure 4.1B were done as follows (reservoirs not having a
potential applied were allowed to float). Labeled sample was loaded by applying +400 V to
reservoir 2 and grounding reservoir 1 for 5 min. Rinsing was achieved by applying the same
potential to reservoir 2 and grounding reservoir 4. Elution was accomplished by applying +1000
V between reservoirs 5 and 2. For on-chip labeling with this design, unlabeled sample was
loaded as before, then the dye was driven through the column by applying +400 V between
reservoirs 3 and 2. This was followed by rinse and elution as above.

4.2.6 Instrumentation
The laser induced fluorescence system has been described previously.34,

36

A Nikon Eclipse

TE300 inverted microscope equipped with a CCD camera (Coolsnap HQ, Roper Scientific,
Sarasota, FL, USA) was used. A 10x expander was used to increase the laser beam diameter,
which was directed to a 20x, 0.45 NA objective on the microscope. For fluorescence monitoring,
the detection point was positioned either just to the left of reservoir 2 (Fig. 4.1A or B), or directly
on the monolith. The collected CCD images were analyzed using V++ Precision Digital Imaging
software (Auckland, New Zealand).
4.2.7 Data analysis
To evaluate the extent to which different samples sorbed on the monolith, amino acids,
fluorescent dyes and two proteins (BSA and HSP90) were loaded. Their retention was monitored
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via CCD detection by measuring the background-subtracted fluorescent intensity on the monolith
after rinsing.

For protein preconcentration, the background-subtracted steady state fluorescent intensity before
the sample reached the monolith, which is the signal without preconcentration, was compared to
the elution intensity, obtained by subtracting the baseline from the peak maximum. The
calculation of HSP90 concentration for the calibration curve was based on the eluted peak area.

4.3 RESULTS AND DISCUSSION
4.3.1 Preparation of monoliths
I fabricated thermally bonded COC microdevices38 with reversed-phase monolithic columns for
SPE. COC was chosen because of its resistance to common organic solvents like acetonitrile25
that are normally used for elution in SPE. Fabrication of a 2 mm long monolith in these
microchips was done with a ternary porogenic solvent system consisting of dodecanol,
cyclohexanol, and Tween 20.39 Optimization of these porogens was carried out by Pagaduan et
al.39 who found that the monoliths formed were porous enough for water and buffer to flow
through by capillary action. The monolith was made from a mixture consisting of a 60:40
porogen-to-monomer ratio, which provided more surface area and hence sample binding sites
than monoliths with a higher ratio.40 Importantly, experiments carried out in my monoliths
showed that the application of voltage did not cause movement of the monolith, in agreement
with Ladner et al.26 Thus, pretreatment methods like photografting24,

26

that complicate

fabrication, adsorb sample and cause channel clogging were avoided. The monolithic structure
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seen in Figure 4.2 showed clusters of globules with irregular through-pores, typical of high
surface area monoliths.

Figure 4.2. SEM image of a BMA monolith showing detailed morphology.
BMA was chosen over other monomers such as MMA and LMA, which formed monoliths with
morphologies shown in Figure 4.3. While MMA showed even packing and large pores, LMA
produced a monolith with small through-pores. Even when the LMA monomer concentration
was reduced to 25%, the very small through-pore dimensions were not favorable for flow. MMA
was the least hydrophobic while LMA was the most hydrophobic of the monoliths fabricated.
When LMA columns were used for protein extraction, elution was difficult because of the strong
hydrophobic interactions with proteins. BMA, therefore, with intermediate properties between
91

MMA and LMA, was best suited for selective retention and elution in these experiments.
Monoliths prepared with BMA and EDMA have been shown to have comparable hydrophobicity
to C18 beads;41 indeed, BMA monoliths have been used for SPE of proteins.5, 42

Figure 4.3. Comparison of monolithic structures with different carbon chain lengths: a) MMA
(40%), b) LMA (40%), and c) LMA (25%). Porosity decreases while surface area increases with
a longer carbon chain. See Figure 4.2 for BMA monolith morphology.
4.3.2 Retention of samples on BMA monoliths
An initial study of column preparation and sample loading conditions for BMA monoliths is
summarized in Figure 4.4. Retention was greatest when the monolith was rinsed with carbonate
buffer containing 30% ACN just before sample loading. It was also observed that samples
dissolved in aqueous carbonate buffer or buffer having≤0.5% ACN showed the best retention,
while samples dissolved in carbonate buffer containing 2% ACN were retained less on the
column. Rinsing reversed-phase monoliths with an ACN-aqueous buffer mixture has been shown
to be necessary for preconditioning,43 removing impurities that may interfere with sorption.
Preconditioning with ACN also helps to activate and/or hydrate the monolith surface to provide
adequate contact with the liquid sample.44
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Figure 4.4. Effect of column preparation and sample loading conditions on retention for BMA
monoliths. Sample was 1 µg/mL BSA. (A) Monolith rinsed with buffer (10 mM carbonate, pH
9.3) before loading. (B) Monolith rinsed with buffer solution containing 30% ACN followed by a
thorough rinse with buffer. (C) Monolith rinsed with 30% ACN in buffer just before loading. (1)
Sample dissolved in buffer containing no ACN, (2) sample dissolved in buffer containing 2%
ACN, and (3) sample dissolved in buffer containing 0.5% ACN. Best retention was observed
when the monolith was rinsed with ACN-containing buffer just before sample loading. ACN
concentrations up to 0.5% in buffer did not significantly affect retention.

Figure 4.5 shows the normalized retention of fluorescent dyes, amino acids and proteins on BMA
monoliths. Retention of the fluorescent dyes (Fig. 4.5A) on the column was relatively low.
Unreacted (free) Chromeo P503 has a low fluorescence signal,45 which explains its limited
retention. The ionic sodium salt of fluorescein used does not partition significantly into the
hydrophobic BMA column, accounting for its low retention. The slightly higher fluorescent
intensities observed for Alexa Fluor 488 TFP ester and FITC are likely due to small differences
in experimental conditions.
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Figure 4.5. Normalized retention of a) fluorescent dyes, and b) amino acids and proteins on an
on-chip BMA column. Loading was the same for all samples, except the polarity was reversed
for Chromeo P503. Values were normalized to 100 nM dye concentration in (a) and 100 ng/mL
amino acid or protein concentration in (b).
Retention of amino acids (Fig. 4.5B) on my BMA monolith depended on their hydrophobicity.
Hydropathicity index, a measure of hydrophobicity of amino acids and proteins,46 can predict
their expected interaction with the monolith. More hydrophobic compounds have a more positive
index value. Low retention was observed for aspartic acid and glycine, which have hydrophilic
values of -3.5 and -0.4, respectively. As expected, phenylalanine, with an index of 2.8, was
retained more. The two proteins in Figure 4.5B were more highly retained on BMA monoliths
than any amino acids. Protein binding comes from the average surface hydrophobicity, which
combines the contributions of all the amino acids present on the surface.47 Some of these amino
acids, such as phenylalanine, alanine, and methionine, are hydrophobic and form hydrophobic
regions or “patches” on protein surfaces.48, 49 The non-specific sorption of proteins like BSA to
hydrophobic surfaces has been shown to be the result of interactions between these hydrophobic
patches and surface.50 These more extensive hydrophobic surface interactions for the two
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proteins studied (relative to the free amino acids) result in their greater retention on these
monoliths. I determined the protein loading capacity of our 2 mm long monoliths to be 2 μg (30
pmol) of BSA.

4.3.3 Elution of samples
Figure 4.6 shows elution profiles of fluorescent dyes on a BMA column. The areas of the eluted
peaks were correlated with the amount retained (see Fig. 4.5A). The elution profiles of some
amino acids and the proteins, BSA and HSP90, from a BMA monolith can be seen in Figure 4.7.
The areas of the eluted amino acid peaks (Figure 4.7A) followed the order of the amount retained
(Fig. 4.5B) with aspartic acid having the lowest elution intensity and phenylalanine the highest.
The earlier elution of HSP90 compared to BSA (Fig. 4.7B) is likely due to the fact that HSP90
has a greater negative charge density,51 and is not only more hydrophilic but also migrates faster
in an electric field, both factors in electrochromatography.52 A comparison of the intensities of
the peaks at elution (Fig. 4.7B) to the signal before the sample reached the monolithic column
gave the degree of preconcentration of each protein. The calculated enrichment factors were 11fold for HSP90 and 6-fold for BSA, demonstrating that these proteins were concentrated on the
reversed-phase column. The degree of preconcentration of HSP90 was higher than for BSA
because it eluted in a ~2-fold narrower band, since it was less retained than BSA. It is expected
that with longer columns and loading times the degree of preconcentration could be even greater.
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Figure 4.6. Elution profiles of fluorescent dyes from an on-chip BMA column. All signals were
normalized to 100 nM dye concentration, as in Figure 4.5. Dyes (from bottom to top) are:
Chromeo P503, fluorescein, FITC, and Alexa Fluor 488 TFP. Chromatograms are offset
vertically for clarity. Positively charged Chromeo P503 dye was eluted with application of a
negative voltage, while all others (negatively charged) required a positive voltage. The first 30 s
of Chromeo P503 dye elution is expanded in the inset.
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Figure 4.7. Elution profiles of amino acids and two proteins (BSA and HSP90) from an on-chip
BMA monolith. a) Chromatograms of amino acids (100 ng/mL) from bottom to top are: aspartic
acid, glycine, and phenylalanine. Chromatograms are offset vertically for clarity. b) Elution of 1
µg/mL proteins (BSA – maximum around 55 s, and HSP90 – maximum around 30 s).
4.3.4 Off- and on-chip labeling with Chromeo P503
Figure 4.8 shows elution profiles for BSA labeled off- and on-chip with Chromeo P503 dye.
Although Chromeo P503 dye is positively charged, after reaction with BSA the labeled protein is
negatively charged at pH 9.3. Elution of Chromeo P503-labeled BSA from the column (Fig.
4.8A) is slower than Alexa Fluor 488-labeled BSA (Fig. 4.7B) because Chromeo P503-labeled
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protein has less negative charge.53, 54 Figure 4.8B shows that the elution of BSA labeled on-chip
with Chromeo P503 is similar to that for protein labeled off-chip. For on-chip labeling, the
oppositely charged Chromeo P503 and labeled protein migrate in opposite directions under the
elution voltage, simplifying purification. This use of charge to selectively elute proteins relative
to dye makes on-chip labeling of protein samples with Chromeo P503 appealing.

Figure 4.8. Elution profiles of 1 µg/mL BSA labeled a) off-chip and b) on-chip with Chromeo
P503 dye.

98

4.3.5 On-chip labeling with Alexa Fluor 488 TFP ester
Alexa Fluor 488, which produces very bright and photostable conjugates,55,

56

was used with

HSP90 to demonstrate proof of principle of on-chip preconcentration, labeling and purification
of protein from label within an integrated microfluidic platform. Figure 4.9 shows the elution of
different concentrations of on-chip labeled HSP90 from a BMA column. A 15 min on-chip
labeling of 1 µg/mL HSP90 with Alexa Fluor 488 TFP ester in Fig. 4.9A showed two peaks, the
dye followed by HSP90. On-chip labeling of different concentrations of HSP90 retained on a
BMA monolith showed increasing peak areas with concentration. A plot of peak area against
HSP90 concentration (Fig. 4.9B) was linear, showing that concentration and signal can easily be
correlated for an unknown sample after on-chip labeling. I note that these systems could be used
to concentrate and label other proteins in a similar manner. Retention of more sample could be
attained by increasing the surface area of the monolith through adjustment of polymerization
conditions or usage of different branched crosslinkers, as demonstrated by Lee’s group.57, 58

Figure 4.9. On-chip labeling and elution of HSP90 using a BMA column. a) Elution traces.
Chromatograms are offset vertically for clarity (bottom: 0.1 μg/mL, middle: 0.5 μg/mL and top:
1 μg/mL). b) Plot of peak area as a function of HSP90 concentration. The slope is 7200 ± 140,
and the intercept is 830 ± 170.
99

Unlike typical on-chip labeling where the on-line mixing of high concentrations of fluorescent
dyes with sample can interfere with the separation process, in my work protein samples are
enriched in addition to being labeled and purified from the unreacted dye. These results
demonstrate that unlabeled protein samples can be readily assayed by a simple and sensitive
procedure that is favorable for automation. Integration of my reversed-phase columns with an
up-stream affinity extraction module would further increase the selectivity of the method,
especially for complex biological samples. Multiple analytes could also be extracted, labeled and
separated in my integrated system.
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5. CONCLUSIONS AND FUTURE WORK

5.1 CONCLUSIONS
5.1.1 Integrated affinity and electrophoresis systems for biomarker analysis
In Chapter 2, I reviewed the principles and protocols for the fabrication of PMMA devices and
preparation of porous monolithic columns in the devices. Designs on a silicon template, prepared
by photolithographic techniques and etching, were transferred to a PMMA piece by hot
embossing. The embossed piece was then sealed to a cover plate by thermal bonding. Affinity
columns were prepared in these devices by in situ photopolymerization of a prepolymer mixture
containing glycidyl methacrylate monomer containing epoxy groups that react with protein
amine groups. The columns were functionalized with antibodies and used for the extraction of
fluorescently labeled cancer biomarkers. Labeling efficiency was determined by performing
electrophoresis without affinity extraction. Efficient labeling of the proteins occurred at pH ~9
but TK1 with a higher pI of ~8.75 was better labeled at a higher pH of 10.6. µCE of Alexa Fluor
488-labeled TK1 showed complete separation of the unreacted dye and the labeled protein.
Initial affinity extraction experiments with anti-HSP90 functionalized monoliths showed
specificity towards HSP90 but not to the unreacted dye. Such systems show great promise for
analysis in complex mixtures.

5.1.2 Ion-permeable membrane for on-chip preconcentration and separation of cancer
marker proteins
I demonstrated that cancer marker proteins can be electrophoretically concentrated and separated
in a microdevice using a simple and quick method. On-chip preconcentration was achieved with
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an ion-permeable membrane formed by in situ photopolymerization just beyond the injection
intersection in the microchip. Baseline resolution of two cancer marker proteins with similar
electrophoretic mobilities was accomplished at pH 7.0. A 10-fold increase in the signal of these
proteins was achieved under my optimized conditions with just a 1 min preconcentration time.
Such signal enhancement offers improved limits of detection that are essential in clinical
diagnosis where target proteins can be present in low concentrations. The preconcentration and
separation process carried out with my device is simple, fast, and generalizable. The simplicity
and speed of analysis provide good potential for application in POC analysis. The membrane
used in this device could easily be coupled to a suitable pretreatment technique, such as affinity
extraction, for the analysis of clinically significant biomolecules in a complex sample matrix.
This technique offers the potential for enhanced analysis of multiple cancer biomarkers, which
should facilitate diagnosis and monitoring of response to treatment.

5.1.3 Microfluidic chips with reversed-phase monoliths for solid phase extraction and onchip labeling
The difficulties encountered in the integration of sample preparation methods in microfluidic
systems present a significant obstacle to miniaturized analysis. Therefore, effective integration of
sample labeling moves the field closer to the automation level necessary for application in pointof care diagnostics, for example. I have presented a miniaturized system that combines sample
enrichment with on-chip labeling and purification. Samples are enriched through SPE on a BMA
monolith in a microfluidic device. Analytes are fluorescently labeled while they are on the
column, and much of the unreacted dye is removed in a rinsing step. The labeled protein is more
strongly retained compared to the unattached label, enabling further purification during elution. I
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have characterized the retention and elution of fluorophores and fluorescently labeled amino
acids and proteins. I have also developed conditions for automated on-chip fluorescent labeling
and purification of proteins. Importantly, the eluted peak area for on-chip labeled HSP90 scaled
linearly with concentration, demonstrating the ability of my method to quantify on-chip labeled
samples. The combination of the proven enrichment capacity of SPE with fast labeling and
separation yields a simple technique that is well suited for miniaturization. The integration of this
approach with affinity extraction should provide an additional dimension of specificity,
providing a powerful and automated method for bioanalysis.

5.2 FUTURE WORK
5.2.1 Affinity extraction coupled with solid phase extraction, on-chip labeling and µCE
In Chapter 2, I provided the protocol for the preparation of porous monolithic columns and their
subsequent functionalization with antibodies. Extraction from complex biological samples is
easier with a wall-coated column because clogging is not an issue. However, the surface area for
antibody immobilization is higher with porous monolith, resulting in the extraction of more
analyte. If the pores are large enough, clogging can be avoided. Serial arrangement of an affinity
column and a reversed phase column could enable automated determination of analyte
concentrations from complex mixtures. Samples could be extracted, concentrated and labeled onchip, reducing sample loss and overall analysis time compared to off-chip sample preparation
methods. Figure 5.1 shows a schematic of a device that could be used for this purpose. Monolith
1 could be made from monomers containing epoxide groups such as glycidyl methacrylate1 or
azlactone groups such as 2-vinyl-4,4-dimethylazlactone,2,3 which can react with amine groups on
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antibodies as described in Section 2.3.3. Monolith 2 would be reversed phase as described in
chapter 4.

Figure 5.1. Schematic of a device for coupling affinity extraction with solid phase extraction,
on-chip labeling and µCE.
Application of voltage between the sample and waste 1 reservoirs will cause the sample to flow
through monolith 1 (affinity) where the protein of interested will be extracted. Rinsing of excess
sample will be done by applying voltage between rinse 1 and waste 1 reservoirs. By applying
voltage between eluent 1 and waste 2 reservoirs the sample will be eluted from the affinity
column and trapped on the reversed-phase column (monolith 2) where it could be further labeled
on-chip by application of voltage between the label and waste 2 reservoirs. Rinsing of excess
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label will be performed by the application of voltage between rinse 2 and waste 2 reservoirs. The
concentrated sample could then be eluted into the µCE system by application of voltage between
the eluent 2 and injection waste reservoirs. The “pinched” injection method could be used to
move the sample into the separation channel for µCE. Detection could be carried out near the
buffer reservoir with the same LIF system described in Section 2.3.5.

5.2.2 On-chip protein digestion coupled with solid phase extraction and µCE
In Chapter 4, I showed that proteins could be concentrated on a monolithic column, fluorescently
labeled and then separated. It should be possible for protein identification to be carried out by
fragmenting the protein and analyzing the resulting peptide units.4 This method, known as
shotgun or bottom-up proteomics,4 requires digestion of the protein sample and subsequent
analysis of the fragments by MS, after separation, for example by HPLC or capillary
electrophoresis. A proteolytic enzyme in solution is commonly used for protein digestion.1
However, digestion by this method is slow, and autodigestion is common, resulting in unwanted
products.1 Solid-phase microreactors with immobilized proteolytic enzymes have been shown to
rapidly digest proteins as well as prevent autodigestion.2 Moreover, because of the high enzymeto-substrate ratio in solid-phase microreactors, the digestion efficiency is high.5 Several solid
supports have been employed in microfluidic systems for the digestion of proteins including
agarose beads,6 micropost structures,5 fiberglass7 and polymer monoliths.1,3 The ease of
fabrication of monolithic columns in microdevices gives it an advantage over the other solid
supports.
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Two monoliths fabricated in series could be used for protein digestion and solid phase extraction
of the generated peptide fragments. The first monolith could be prepared as before (see Section
2.3.3) to react with amine groups on proteolytic enzymes such as pepsin8 or trypsin.2 The second
monolith would be the same type of reversed phase monolith described in chapter 4. A schematic
of a device design that could be used for these experiments is shown in Figure 5.2. Application
of voltage between the sample and waste reservoirs will cause the sample to flow through
monolith 1 (enzyme-functionalized) where the protein will be digested as it flows towards
monolith 2. The fragmented sample will be trapped on monolith 2. The fragments on monolith 2
will be labeled by applying a voltage between the label and waste reservoirs, and the lightly
retained label will be rinsed off by the application of voltage between the rinse and waste
reservoirs. Elution of labeled fragments will be done by applying voltage between the eluent and
injection waste reservoirs, and the eluted fragments will be injected into the separation column
by “pinched” injection where they will be separated by µCE.

Though digestion efficiencies may be high, it is difficult to achieve 100% digestion, so the
resulting mixture will consist of multiple peptides along with some undigested protein.
Separation efficiencies for such complex mixtures are lower with shorter separation channels,9 so
a serpentine separation channel will be used to improve resolution. Detection will be carried out
by the LIF system described in Section 2.3.5.
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Figure 5.2. Schematic of a device for coupling protein digestion with solid phase extraction, onchip labeling and µCE.
5.2.3 On-chip immuno-extraction coupled with protein digestion, preconcentration and MS
detection
Mass spectrometry has been successfully applied to protein identification because the method is
accurate and can give information about post-translational modification.6 However, its efficiency
is improved if the sample is fractionated and separated before detection.10 Mellors et al.11, 12 have
shown that µCE can be coupled to ESI-MS by directing the separation channel to the corner of
the microdevice to serve as the electrospray tip. An EOF pump at the junction between three
channels facilitated the transfer of solution to the ESI emitter.
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Analysis of biological samples would be simplified with initial purification to obtain the desired
analyte, as demonstrated by the use of immunoaffinity columns.13 Immuno-extraction of a
specific protein followed by on-chip digestion and MS detection would present a rapid and
efficient means of determining small structural differences between proteins such as variants,
isoforms and post-translational modifications. It is important to be able to identify these subtle
changes because as a disease progresses protein modifications also can occur.14 Additionally,
knowing the location of post-translational modification within a protein can provide useful
information for some biochemical processes.6 With the use of three monolithic columns proteins
could be extracted, digested and concentrated on-chip before MS detection. A schematic of such
a device is shown in Figure 5.3. Monoliths 1 and 2 could both be made as before (Section 2.3.3)
to facilitate reaction with amine groups on antibodies (monolith 1) and proteolytic enzymes
(monolith 2). Monolith 3 would be the same type of reversed phase monolith described in
chapter 4. Monolith 1 would be functionalized with an antibody that targets a specific analyte
while monolith 2 would be functionalized with a proteolytic enzyme. A complex biological
sample would be loaded on monolith 1 by application of voltage between the sample and waste 1
reservoirs, enabling specific extraction. Lightly retained sample would be removed by
application of voltage between the rinse and waste 1 reservoirs. The protein can then be eluted
from the column by application of voltage between eluent 1 and waste 2 reservoirs. In this
process the eluted protein would flow through monolith 2, where it would be digested, and move
on to monolith 3 to be trapped and concentrated. Coupling of µCE with MS could be done by
eluting the sample into the injection intersection by the application of voltage between the eluent
2 and injection waste reservoirs. The eluted fragments will be injected into the separation column
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by “pinched” injection where they will be separated by µCE. The separation voltage would be
applied between the ground and side channel reservoirs. The side channel would be positioned so
that it meets the separation channel at a point that is close to the outlet leading to the MS system,
so that sample can be sprayed into the MS system as it reaches the junction.

Figure 5.3. Schematic of a device for coupling on-chip affinity extraction with MS detection.
In summary, my research has been aimed at developing techniques for the integration of sample
preparation methods in microchips. Sample preconcentration has been achieved by in situ
preparation of hydrogel membranes and polymer monoliths. In addition, fluorescent labeling
which is typically performed off-chip has been integrated and coupled with purification and
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µCE. Further studies in the combination of affinity extraction with preconcentration and on-chip
labeling will advance the applications of micro total analysis systems, and lead to rapid
determination of biomarkers. The coupling of microfluidics with mass spectrometry should also
advance proteomics by enabling the determination of protein structures and providing further
insight into biochemical processes.
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